Official Protocol Title:  
NCT number:  [STUDY_ID_REMOVED]  
Document Date:  01-Jun-2018A Phase 3, Multicenter, Randomized, Double-blind, Active 
Comparator-controlled Study to Evaluate the Safety, Tolerability, 
and Immunogenicity of V114 Followed by [CONTACT_63491]™23 One Year Later in Healthy Adults 50 Years of
Age or Older (PNEU-PATH)
PRODUCT: V114 1
PROTOCOL/AMENDMENT N O.:016-01
V114 -016-01-FINAL PROTOCOL01-JUN-2018
Title Page
THIS PROTOCOL AMENDMENT AND ALL OF THE INFORMATION RELATING 
TO IT ARE CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK 
SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC., NJ, U.S.A. 
(MSD).
Protocol Title: A Phase 3, Multicenter, Randomized, Double -blind, Active Comparator -
controlled Study  to Evaluate the Safet y, Tolerability , and Immunogenicit y of V114 Followed 
by [CONTACT_63492]™23 One Year Later i n Healthy  Adults 50 Years of 
Age or Older (PNEU -PATH)
Protocol Number: 016-01
Compound Number: V114
Sponsor Name:
[CONTACT_19519] & Dohme Corp., a subsidiary  of [COMPANY_006] & Co., Inc.
(hereafter referred to as the Sponsor or MSD)
Legal Registered Address:
One [COMPANY_006] Drive
[PO_BOX]
Whitehouse Station, New Jersey , [ZIP_CODE] -0100, U.S.A.
Regulatory Agency Identifying Number(s):
IND
EudraCT: [ZIP_CODE]
2017 -004024 -30
Approval Date: 01-JUN -[ADDRESS_68472]: V114 2
PROTOCOL/AMENDMENT N O.:016-01
V114 -016-01-FINAL PROTOCOL01-JUN-2018
Sponsor Signatory
Typed Name:
[CONTACT_1641]:Date
Protocol -specific Sponsor contact [CONTACT_63493] (or equivalent).
Investigator Signatory
I agree to conduct this clinical study in accordance with the design outlined in this protocol 
and to abide b y all provisions of this protocol.
Typed Name:
[CONTACT_1641]:Date 
  04Y2RW 
  05KFF2
PRODUCT: V114 3
PROTOCOL/AMENDMENT N O.:016-01
V114 -016-01-FINAL PROTOCOL01-JUN-2018
PROTOCOL AMENDMENT S UMMARY OF CHANGES
Amendment: 01
Overall Rationale for the Amendments:
The primary  purpose of this amendment is to remove the collection of medical device incidents from the protocol (removal of Section 
6.1.1, Section 8.4.8, and Appendix 4 ). The implementation of the FDA guidance forreporting events related to combination products 
has been delay ed until January  2020. Therefore, the current protocol is not within the scope of medical device reporting requirements . 
Other clarifications and editorial revisions were also made as shown in the Summary  of Changes Table b elow.
Summary of Changes Table:
Section # and Name [CONTACT_11029]  
2.2.1 V114 and Pneumococcal Disease Licensure dates for Prevnar 13™ were added 
to the third paragraph.
Revisions were made in the fourth paragraph
tobetter align with the cited literature.Revision smade for accuracy .
[IP_ADDRESS] Immunogenicit y Endpoints The following revision has been made to the 
first sentence ( revision in bold ):
Sera from participants will be used to measure 
vaccine -induced, serot ype-specific OPA and 
IgG responses for all 15 seroty pes (1, 3, 4, 5, 
6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F,
and 33F) included in V114 using the 
Multiplexed Opsonophagocy tic Assay  
(MOPA) assay  and pneumococcal 
electrochemiluminescence (PnECL) assay .Revision made for accuracy . 
  04Y2RW 
  05KFF2
PRODUCT: V114 4
PROTOCOL/AMENDMENT N O.:016-01
V114 -016-01-FINAL PROTOCOL01-JUN-2018
Section # and Name [CONTACT_11029]  
5.2Exclus ion Criteria The following addition has been made (in 
bold ) to Exclusion Criterion #9: 
9.Received s ystemic corticosteroids 
(prednisone equivalent o f ≥20 mg/day ) for 
≥[ADDRESS_68473] 30 day s before study  
entry .Added for consistency  with other 
sections to clarify  the specific steroid 
used as a reference.
6.1.1 Medical Devices
8.4.8 Medical Device Incidents 
(Including Malfunctions)
10.4 Appendix 4: Medical Device 
Incidents: Definition and Procedures for 
Recording, Evaluating, Follow -up, and 
ReportingSection sremoved . The implementation of the FDA 
guidance for reporting events related to 
combination products has been delay ed 
until January  2020. Therefore, the 
current protocol is not within the scope 
of medical device reporting 
requirements.
6.5Concomitant Therap y The following addition has been made ( in 
bold ) to #3:
3.Participants should not recei ve systemic 
corticosteroids ( prednisone equivalent of ≥20 
mg/day  for ≥14 consecutive day s) starting 
from [ADDRESS_68474]: V114 5
PROTOCOL/AMENDMENT N O.:016-01
V114 -016-01-FINAL PROTOCOL01-JUN-2018
Section # and Name [CONTACT_11029]  
8.1.[ADDRESS_68475] Questionnaire
1.3 Schedule of Activities (SoA)The text in Section 8.1.10 was revised as 
follows:
Original : All participants will be contact[INVESTIGATOR_530] b y 
telephone at Month [ADDRESS_68476] Questionnaire. Data to be 
reported on this questionnaire will include 
SAEs and/or an y updates to concomitant 
medications, nonstudy  vaccinations, and 
previously  reported safety  information.
Revised : Site personnel will contact [CONTACT_63494] a Telephone Contact [CONTACT_63495] b y the Sponsor. Data to be reported 
from this discussion will include SAEs and/or 
any updates to concomitant medications, 
nonstudy  vaccinations, and previously  
reported safet y information.
The revised tex t was also added to the SoA.Revisions were made to clarify  the 
process for administering the telephone 
contact [CONTACT_63496]. 
  04Y2RW 
  05KFF2
PRODUCT: V114 6
PROTOCOL/AMENDMENT N O.:016-01
V114 -016-01-FINAL PROTOCOL01-JUN-2018
Section # and Name [CONTACT_11029]  
8.4.1 Time Period and Frequency  for 
Collecting AE, SAE, and Other Reportable 
Safety  Event InformationThe following text was del eted from the 
second paragraph in this section:
All AEs, SAEs, and other reportable safety  
events must be reported by  [CONTACT_63497]/randomization to 
the first vaccination and from the day  of each 
vaccination through 14 day s (42 day s for live 
attenuated vaccines) postvaccination.  SAEs 
must also be reported throughout the duration 
of the individual’s participation in the study , 
regardless of whether or not related to the 
Sponsor’s product.Live attenuated vaccines are not 
provid ed as part of the study .
8.5Treatment of Overdose The definition of overdose was revised as 
follows:
Original : In this study , an overdose is any  
dose higher than 1 dose of an y individual 
study  vaccine during the individual’s 
participation in the study .
Revised : In this study , an overdose is the 
administration of more than [ADDRESS_68477]: V114 7
PROTOCOL/AMENDMENT N O.:016-01
V114 -016-01-FINAL PROTOCOL01-JUN-2018
Section # and Name [CONTACT_11029]  
9.4.1 Immunogenicit y Endpoints The following sentence was added:
Immune responses will be measured for each 
of the following serot ypes contained in V114: 
1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 
22F, 23F, and 33F.Text added to clarify  that immune 
responses will be tested for the 
seroty pes contained in V114 and not 
for all of the PNEUMOVA X™23 
seroty pes.
9.6.2 Statistical Meth ods for Safet y 
Analy ses, Table 5Tier 2 safety  endpoint was revised as follows 
(changes in bold ):
“Any SAE and vaccine -related AE” was 
changed to “ Any vaccine -related SAE ”Table was revised to align with safet y 
analysis plan and text under Tier [ADDRESS_68478]: V114 8
PROTOCOL/AMENDMENT N O.:016-01
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
Table of Contents
PROTOCOL AMENDMENT S UMMARY OF CHANGES ............................................... 3
1 PROTOCOL SUMMARY ............................................................................................ 15
1.1 Synopsis ................................................................................................................. 15
1.2 Schema .................................................................................................................. 20
1.3 Schedule of Activities (SoA) ................................................................................ 21
2 INTRODUCTION .......................................................................................................... 25
2.1 Study Rationale .................................................................................................... 25
2.2 Background .......................................................................................................... 25
2.2.1 V114 and Pneumococcal Disease ................................................................ 25
2.2.2 Preclinical and Clinical Studies ................................................................... 26
2.2.3 Information on Other Study -related Therap y.............................................. 27
[IP_ADDRESS] Prevnar 13™ ...................................................................................... 27
[IP_ADDRESS] PNEUMOVAX™23 .......................................................................... 27
2.3 Benefit/Risk Assessment ...................................................................................... 28
3 HYPOTHESIS, OBJECTIV ES, AND ENDPOINTS ................................................. 28
4 STUDY DESIGN ............................................................................................................ 30
4.1 Overall Design ...................................................................................................... 30
4.2 Scientific Rationale for Study Design ................................................................ .31
4.2.1 Rationale for Endpoints ............................................................................... 31
[IP_ADDRESS] Immunogenicit y Endpoints ................................................................ 31
[IP_ADDRESS] Safety  Endpoints ................................................................................ 32
[IP_ADDRESS] Future Biomedical Research .............................................................. 32
4.2.2 Rationale for the Use of Comparator ........................................................... 32
4.3 Justification for Dose ........................................................................................... 33
4.4 Beginning and End of Study Definition ............................................................. 33
4.4.1 Clinical Criteria for Early Study Termination ............................................. 33
5 STUDY POPULATION ................................................................................................ 33
5.1 Inclusion Criteria ................................................................................................ .33
5.2 Exclusion Criteria ................................................................................................ 34
5.3 Lifestyle Considerations ...................................................................................... 36
5.4 Screen Failures ..................................................................................................... 36
5.5 Participant Replacement Strategy ...................................................................... 36
6 STUDY INTERVENTION ............................................................................................ 36
6.1 Study Intervention(s) Administered ................................................................... 36
6.2 Preparation/Handling/Storage/Accountability ................................................. [ADDRESS_68479]: V114 9
PROTOCOL/AMENDMENT N O.:016-01
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
6.2.1 Dose Preparation .......................................................................................... 38
6.2.2 Handling, Storage, and Accountability ........................................................ 38
6.3 Measures to Minimize Bias: Randomization and Blinding .............................. 38
6.3.1 Intervention Assignment.............................................................................. 38
6.3.2 Stratification ................................................................................................ .39
6.3.3 Blinding ........................................................................................................ 39
6.4 Study Intervention Compliance .......................................................................... 39
6.5 Concomitant Therapy .......................................................................................... 40
6.5.1 Rescue Medications and Supportive Care ................................................... 40
6.6 Dose Modification (Escalation/Titration/Other) ............................................... [ADDRESS_68480] to Follow -up................................................................................................ .42
8 STUDY ASSESSMENTS AN D PROCEDURES ........................................................ 43
8.1 Administrative and General Procedures ........................................................... 44
8.1.1 Informed Consent ......................................................................................... 44
[IP_ADDRESS] General Informed Consent ................................................................ .44
[IP_ADDRESS] Consent and Collection of Specimens for Future Biomedical 
Research ............................................................................................. 44
8.1.2 Inclusion/Exclusion Criteria ........................................................................ [ADDRESS_68481] ..................................................................... 45
8.1.4 Medical History ........................................................................................... 45
8.1.5 Prior and Concomitant Medications Review ............................................... 45
[IP_ADDRESS] Prior Medications ............................................................................... 45
[IP_ADDRESS] Concomitant Medications .................................................................. 45
8.1.6 Assignmen t of Screening Number ............................................................... 45
8.1.7 Assignment of Treatment/Randomization Number ..................................... 46
8.1.8 Study  Intervention Administration .............................................................. 46
[IP_ADDRESS] Timing of Dose Administration ......................................................... [ADDRESS_68482] Questionnaire ................................................................ 47
8.1.11 Discontinuation and Withdrawal ................................................................ .47
[IP_ADDRESS] Withdrawal From Future Biomedical Research ................................ 48
8.1.12 Participant Blinding/Unblinding .................................................................. [ADDRESS_68483]: V114 10
PROTOCOL/AMENDMENT N O.:016-01
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
8.1.13 Calibration of Equipment ............................................................................. 49
8.2 Immunogenicity Assessments ............................................................................. 49
8.2.1 Multiplex Opsonophagocytic Assay (MOPA) ............................................. 49
8.2.2 Electrochemiluminescence (ECL) ............................................................... [ADDRESS_68484] ............................................................................................. 51
8.3.3 Body Temperature Measurement ................................................................ .51
8.3.4 Safety  Assessments and Use of the eVRC ................................................... 51
8.3.5 Clinical L aboratory  Assessments ................................................................ .52
8.4 Adverse Events (AEs), Serious Adverse Events (SAEs), and Other 
Reportable Safety Events .................................................................................... 52
8.4.1 Time Period and Frequency  for Collecting AE, SAE, and Other 
Reportable Safet y Event Information .......................................................... 52
8.4.2 Method of Detecting AEs, SAEs, and Other Reportable Safet y Eve nts......54
8.4.3 Follow -up of AE, SAE, and Other Reportable Safety  Event Information ...55
8.4.4 Regulatory  Reporting Requirements for SAE ............................................. 55
8.4.5 Pregnancy  and Exposure During Breastfeeding .......................................... 55
8.4.6 Disease -related Events and/or Disease -related Outcomes Not Qua lifying 
as AEs or SAEs ............................................................................................ [ADDRESS_68485] (ECI s)................................................................ 56
8.5 Treatment of Overdose ........................................................................................ 56
8.6 Pharmacokinetics................................................................................................ .56
8.7 Pharmacodynamics .............................................................................................. 56
8.8 Future Biomedical Research Sample Collection ............................................... 56
8.9 Planned Genetic Analysis Sample Collection .................................................... 56
8.10 Biomarkers ........................................................................................................... 56
8.11 Medical Resource Utilization and Health Economics ....................................... 56
8.12 Visit Requirements ............................................................................................... 57
8.12.1 Screening ...................................................................................................... 57
8.12.2 Treatment Period/Vaccination Visit ............................................................ 57
8.12.3 Discontinued Participants Continuing to be Monitored in the Study .......... 57
9 STATISTICAL ANALYSIS PLAN ............................................................................. 57
9.1 Statistical Analysis Plan Summary..................................................................... 57
9.2 Responsibility for Analyses/In -house Blinding ................................................. 59
9.3 Hypotheses/Estimation ........................................................................................ [ADDRESS_68486]: V114 11
PROTOCOL/AMENDMENT N O.:016-01
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
9.4.2 Safety  Endpoints .......................................................................................... 60
9.5 Analysis Populations ............................................................................................ 61
9.5.1 Immunogenicit y Analysis Populations ........................................................ 61
9.5.2 Safety Anal ysis Populations ........................................................................ 62
9.6 Statistical Methods ............................................................................................... 62
9.6.1 Statistical Methods for Immunogenicit y Anal yses...................................... 62
9.6.2 Statistical Methods for Safety Anal yses...................................................... 64
9.6.3 Demographic and Baseline Characteristics ................................................. 67
9.7 Interim Analyses .................................................................................................. 67
9.8 Multiplicity ........................................................................................................... 67
9.9 Sample Size and Power Calculations ................................................................ .68
9.9.1 Sample Size and Power for I mmunogenicity  Analy ses............................... 68
9.9.2 Sample Size and Power for Safet y Anal yses............................................... 68
9.10 Subgroup Analyses ............................................................................................... 69
9.11 Compliance (Medication Adherence) ................................................................ .69
9.12 Extent of Exposure ............................................................................................... 69
10 SUPPORTING DOCUMENTA TION AND OPERATIONAL
CONSIDERATIONS ..................................................................................................... 70
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ........ [ADDRESS_68487] for Clinical Trials ............................................................. 70
10.1.2 Financial Disclosure ..................................................................................... 72
10.1.3 Data Protection ............................................................................................. 72
[IP_ADDRESS] Confidentiality  of Data ...................................................................... 73
[IP_ADDRESS] Confidentiality  of Participant Records ............................................... 73
[IP_ADDRESS] Confidentiality  of IRB/IEC I nformation ............................................ 73
10.1.4 Committees Structure ................................................................................... 73
[IP_ADDRESS] Scientific Advisory  Committee .......................................................... 73
[IP_ADDRESS] Executive Oversight Committee ........................................................ 73
[IP_ADDRESS] External Data Monitoring Committee ............................................... 74
10.1.5 Publication Policy ........................................................................................ 74
10.1.6 Compliance with Study  Registration and Results Posting Requirements ...74
10.1.7 Compliance with Law, Audit, and Debarment ............................................ 75
10.1.8 Data Qualit y Assurance ............................................................................... 75
10.1.9 Source Documents ....................................................................................... 76
10.1.10 Study  and Site Closure ................................................................................. 76
10.2 Appendix 2: Clinical Laboratory Tests .............................................................. 77
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting ............................................................... [ADDRESS_68488]: V114 12
PROTOCOL/AMENDMENT N O.:016-01
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
10.3.1 Definition of AE .......................................................................................... 78
10.3.2 Definition of SAE ........................................................................................ 79
10.3.3 Additional Events Reported ......................................................................... 80
10.3.4 Recording AE and SAE ............................................................................... 80
10.3.5 Reporting of AE, SAE, and Other Reportable Safety  Events to the 
Sponsor ........................................................................................................ 85
10.4 Appendix 4: Medical Device Incidents: Definition and Procedures for 
Recording, Evaluating, Follow -up, and Reporting ........................................... 87
10.5 Appendix 5: Contraceptive Guidance and Pregnancy Testing ........................ 88
10.5.1 Definitions .................................................................................................... 88
10.5.2 Contraception Requirements ........................................................................ 88
10.5.3 Pregnancy  Testing ........................................................................................ 90
10.6 Appendix 6: Collection and Management of Specimens for Future 
Biomedical Research ............................................................................................ 91
10.7 Appendix 7: Country -specific Requirements .................................................... 96
10.8 Appendix 8: Abbreviations ................................................................................. [ADDRESS_68489]: V114 13
PROTOCOL/AMENDMENT N O.:016-[ADDRESS_68490] OF TABLES
Table 1 Study  Interventions .......................................................................................... 37
Table 2 Approximate Blood Volumes Drawn b y Stud y Visit and by [CONTACT_63498] ...43
Table 3 Reporting Time Periods and Time Frames for Adverse Events and Other 
Reportable Safet y Events ................................................................................. 54
Table 4 Analy sis Strategy  for Immunogenicit y Variables ............................................ 63
Table 5 Analy sis Strategy for Safety  Param eters Following Each Vaccination ........... 66
Table 6 95% CI s for Vary ing Hypothetical OPA GMT Ratios 
(V114/Prevnar 13™) and Vary ing Standard Deviations with 240 
Evaluable Participants in Each Vaccination Group ......................................... 68
Table 7 Differences in Incidence of AE Rates between the 2 Vaccination Groups 
That Can be Detected With an ~80% Probability  (Assuming 2 -sided 5% 
alpha level with 300 Participants in each Group) ............................................ [ADDRESS_68491]: V114 14
PROTOCOL/AMENDMENT N O.:016-[ADDRESS_68492]: V114 15
PROTOCOL/AMENDMENT N O.:016-01
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
1 PROTOCOL SUMMARY
1.1 Syno psis
Protocol Title: A Phase 3, Multicenter, Randomized, Double -blind, Active Comparator -
controlled Study  to Evaluate the Safet y, Tolerability , and Immunogenicit y of V114 Followed 
by [CONTACT_63492]™23 One Year Later in Healthy  Adults 50 Years of 
Age or Older (PNE U-PATH)
Short Title: Safet y and Immunogenicit y of V114 Followed b y PNEUMOVAX™23
Acronym: PNEUmococcal Conjugate Vaccine Trials : V114 -016 ( PNEU -PATH )
Hypotheses, Objectives ,and Endpoints :
The following objectives and endpoints will be evaluated in health y adults ≥50 y ears of age.
Primary  Objectives Primary  Endpoints
-Objective: To evaluate the safet y and 
tolerability  of V114 compared with 
Prevnar 13™ with respect to the proportion 
of participants with adverse events (AEs).Following vaccination with V114 or 
Prevnar 13™:
-Solicited injection -site AEs from Day  1 
through Day  5 postvaccination
-Solicited sy stemic AEs from Day  1 through 
Day 14 postvaccination
-Vaccine -related serious adverse events 
(SAEs) from Day 1 to Month 12
-Objective: To evaluate the safet y and 
tolerability  of PNEUMOVAX™23 
administered 12 months following V114 
compared with PNEUMOVAX™23 
administered 12 months following 
Prevnar 13™ with respect to the proportion 
of participants with AEs.Following vaccination with 
PNEUMOVAX™23:
-Solici ted injection -site AEs from Day  [ADDRESS_68493]: V114 16
PROTOCOL/AMENDMENT N O.:016-01
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
-Objective: To evaluate the serot ype-specific 
opsonophagocy tic activity  (OPA) Geometric 
Mean Titers (GMTs) at 30 day s 
postvaccination with PNEUMOVAX™23 
(Month 13) for participants administered 
V114 compared with participants 
administered Prevnar 13™ 12 months before 
receipt of PNEUMOVAX™23.-Seroty pe-specific OPA responses for the 
15seroty pes in V114 at Month 13
Secondary  Objectives Secondary  Endpoints
-Objective: To evaluate the serot ype-specific 
Immunoglobulin G (IgG) Geometric Mean 
Concentrations (GMCs) at 30 day s 
postvaccination with PNEUMOVAX™23 
(Month 13) for participants administered 
V114 compared with participants 
administered Prevnar 13™ 12 months before 
receipt of PNEUMOVAX™23.-Seroty pe-specific IgG responses for the 
15seroty pes in V114 at Month 13
-Objective: To evaluate the serot ype-specific 
(1) OPA GMTs and IgG GMCs at 30 day s 
postvaccination (Day 30) and (2) Geometric 
Mean Fold Rises (GMFRs) and proportions 
of participants with a ≥4-fold rise from 
prevaccination (Day  1) to 30 day s 
postvaccination (Day 30) for both OPA and 
IgG responses for participants administered 
V114 and separately for participants 
administered Prevnar 13™.  -Seroty pe-specific OPA and IgG responses 
for the 15 serot ypes in V114 at Day 1 and 
Day 30
-Objective: To evaluate the serot ype-specific 
(1) OPA GMTs and IgG GMCs at 12 mon ths 
postvaccination (Month 12) and (2) GMFRs 
and proportions of participants with a ≥4-fold 
rise from prevaccination (Day  1) to 12 
months postvaccination (Month 12) for both 
OPA and IgG responses for participants 
administered V114 and separately  for 
partic ipants administered Prevnar 13™.-Seroty pe-specific OPA and IgG responses 
for the [ADDRESS_68494]: V114 17
PROTOCOL/AMENDMENT N O.:016-01
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
-Objective: To evaluate the serot ype-specific 
(1) OPA GMTs and IgG GMCs at 30 day s 
postvaccination with PNEUMOVAX™23 
(Month 13),(2) GMFRs and proportions of 
participants with a ≥4-fold rise from 
prevaccination (Day  1) to 30 day s 
postvaccination (Month 13) with 
PNEUMOVAX™23 for both OPA and IgG 
responses, and (3) GMFRs and proportions 
of participants with a ≥4-fold rise from 
prevac cination with PNEUMOVAX™23 
(Month 12) to 30 day s postvaccination with 
PNEUMOVAX™23 (Month 13) for both 
OPA and IgG responses for participants 
administered V114 and separately  for 
participants administered Prevnar 13™ 12 
months before receipt of 
PNEUMOVAX™2 3. -Seroty pe-specific OPA and IgG responses 
for the 15 serot ypes in V114 at Day 1, 
Month 12, and Month 13
Overall Desig n:
Study  Phase Phase [ADDRESS_68495] participant’s last 
study -related telephone call or visit.
For purposes of analy sis and reporting, the overall study  
ends when the Sponsor receives the last serology  assay  
result. 
  04Y2RW 
  05KFF2
PRODUCT: V114 18
PROTOCOL/AMENDMENT N O.:016-01
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
Number of Participant s:
Approximately  600participan ts will be randomized, with approximately  300 participants in 
each intervention group.
Intervention Groups and Du ration :
Intervention 
Group s Intervention 
Group 
Name [CONTACT_63562].Vaccination 
Regimen Use
V114V114Refer to 
IBSingle 
DoseIMSingle Dose at 
Visit 1 (Day 1)Experimental
PNEUMOVAX™23Refer to 
product 
labelingSingle 
DoseIMSingle Dose at 
Visit 3 
(Month 12)Experimental
Prevnar 13™Prevnar 13™Refer to 
product 
labelingSingle 
DoseIMSingle Dose at 
Visit 1 (Day 1)Experimental
PNEUMOVAX™23Refer to 
product 
labelingSingle 
DoseIMSingle Dose at 
Visit 3 
(Month 12)Experimental
IB = Investigator’s Brochure; IM=intramuscular 
Total Number 2intervention groups
Duration of 
ParticipationEach participant will participate in the study  for approximately  13 months from the 
time the participant signs the I nformed Consent F orm ( ICF) through the final 
contact. 
  04Y2RW 
  05KFF2
PRODUCT: V114 19
PROTOCOL/AMENDMENT N O.:016-01
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
Study Governance Committees:
Steering Committee No
Executive Oversight Committee Yes
Data Monitoring Committee Yes
Clinical Adjudication Committee No
Study  governance considerations are outlined in Appendix 1.
Study Accepts Healthy Volunteers :Yes
A list of abbreviations used in this document can be found in Appendix [ADDRESS_68496]: V114 20
PROTOCOL/AMENDMENT N O.:016-[ADDRESS_68497]: V114 21
PROTOCOL/AMENDMENT N O.:016-01
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
1.3 Schedule of Activities (SoA)
Study PeriodInterventionFollow -
up
CommentsVisit Number : 1Telephone 
Contact 2Telephone 
Contact 3Telephone 
Contact 4
Scheduled Time: Day 1 Day 15 Day 30 Month 6 Month 12 Month 12.5 Month 13
Visit Window:Day [ADDRESS_68498] be obtained before the 
blood sample (DNA sample) is 
collected.
Assignment of Screening Number X
Inclusion/Exclusion Criteria X
Medical History
XThe participant’s medical history for 
the [ADDRESS_68499] X
Prior/Concomitant Medication and Non -Study 
Vaccination ReviewX X X X X X X
V114 or Prevnar 13™ Administration (Blinded) 
XAt Visit 1 (Day 1), participants will 
receive either a single dose of V114 or 
a single dose of Prevnar 13™. 
PNEUMOVAX™23 Administration ( Open -
label ) XAt Visit 3 (Month 12), participants will 
receive a single dose of 
PNEUMOVAX™[ADDRESS_68500]: V114 22
PROTOCOL/AMENDMENT N O.:016-01
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
Study PeriodInterventionFollow -
up
CommentsVisit Number : 1Telephone 
Contact 2Telephone 
Contact 3Telephone 
Contact 4
Scheduled Time: Day 1 Day 15 Day 30 Month 6 Month 12 Month 12.5 Month 13
Visit Window:Day [ADDRESS_68501] 
(eVRC)  
X XParticipants will be provided an eVRC 
at Visit 1 (Day 1) and Visit 3 
(Month 12) to record adverse events 
(AEs) and body temperature 
measurements. Instructions for using 
the eVRC will be reviewed with the 
participant.
Review eVRC Data with Participant X X X X
Collect eVRC from ParticipantX X
Complete Telephone Contact [CONTACT_63499] a Telephone 
Contact [CONTACT_63500]. Data to be reported from this 
discussion will include SAEs and/or 
any updates to concomitant 
medications, nonstudy vaccinations, 
and previously reported safety 
information.
Safety Procedures
Complete Physical Examination 
XTo be performed by [CONTACT_63501].
Directed Physical Examination
XTo be performed by [CONTACT_63501]. 
  04Y2RW 
  05KFF2
PRODUCT: V114 23
PROTOCOL/AMENDMENT N O.:016-01
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
Study PeriodInterventionFollow -
up
CommentsVisit Number : 1Telephone 
Contact 2Telephone 
Contact 3Telephone 
Contact 4
Scheduled Time: Day 1 Day 15 Day 30 Month 6 Month 12 Month 12.5 Month 13
Visit Window:Day [ADDRESS_68502] – if applicable
X XA pregnancy test consistent with local 
requirements (sensitive to at least 25 IU 
beta human chorionic gonadotropin [β-
hCG]) must be performed before 
administration of study vaccine in 
females who are of reproductive 
potential. Urine or serum tests can be 
used, and results must be negative 
before vaccination can occur.
Body Temperature Measurement Before 
Vaccination
X XEach participant's body temperature 
must be taken before vaccination. 
Participants who present with fever 
(oral or tympanic temperature ≥100.4°F 
[≥38.0°C]; axillary or temporal 
temperature ≥99.4°F [≥37.4°C]; or 
rectal temperature ≥101.4°F [≥38.6°C]) 
will have the vaccination delayed until 
fever is resolved for 72 hours.
30-Minute Postvaccination Observation PeriodX XTo be performed by [CONTACT_63502].
AE Monitoring
X X X X X X XAEs (serious and non -serious) are to be 
reported from Days 1 through 14 
following each vaccination. SAEs and 
deaths are to be reported throughout the 
duration of an individual’s study 
participation. 
  04Y2RW 
  05KFF2
PRODUCT: V114 24
PROTOCOL/AMENDMENT N O.:016-01
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
Study PeriodInterventionFollow -
up
CommentsVisit Number : 1Telephone 
Contact 2Telephone 
Contact 3Telephone 
Contact 4
Scheduled Time: Day 1 Day 15 Day 30 Month 6 Month 12 Month 12.5 Month 13
Visit Window:Day 15 to 
Day 19 
after Visit 
1aDay 30 
to  Day 
44 after 
Visit 1aDay 166 to 
Day 194 
after Visit 
1aDay 351 to 
Day 379 
after Visit 
1aDay 15 to 
Day 19 
after Visit 
3bDay 30 to  
Day 44 
after Visit 
3b
Immunogenicity Procedures
Serum for immunogenicity assays (including 
retention serum)
X X X XBlood samples must be collected before 
vaccination where applicable. After 
completion of opsonophagocytic ( OPA )
and electrochemiluminescence ( ECL)
testing, serum samples will be stored to 
conduct any additional study -related 
testing as required by [CONTACT_63503]. Leftover sera 
from the study may be used for the 
development and/or validation of 
pneumococcal assays after completion
of all study -related immunogenicity 
testing; this applies only to sera 
received from randomized study 
participants who provided consent for 
future biomedical research.
Future Biomedical Research
Blood (DNA) for Future Biomedical Research
XCollected from randomized participants 
who provided consent for future 
biomedical research (Section 8.8)
aWhen scheduling the Telephone Contact (Day 15), Visit 2 (Day 30), the Telephone Contact (Month 6), and Visit 3 (Month 12), “Day 1” is the date of Visit 1.
bWhen scheduling the Telephone Contact (Month 12.5) and Visit 4 (Month 13), “Day 1” is the date of Visit [ADDRESS_68503]: V114 25
PROTOCOL/AMENDMENT N O.:016-01
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
2 INTRODUCTION
[COMPANY_006] Sharp & Dohme Corp. (MSD) is developi[INVESTIGATOR_63464] 15 -valent 
pneumococcal conjugate vaccine ( PCV )(referred to as V114) for the prevention of 
pneumococcal disease caused by  [CONTACT_63504]. V114 contains the 13 serot ypes 
(1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) present in the licensed vaccine 
Prevnar 13™ (pneumococcal 13 -valent conjugate vaccine [diphtheria CRM 197protein], 
Wyeth Pharmaceuticals, a subsidiary  of [COMPANY_007], Inc., Philadelp hia, PA) , plus 2 additional 
seroty pes (22F, 33F).
2.1 Study Rationale
This study  is conducted in a population (ie, healthy adults ≥50 y ears of age) at elevated risk 
for pneumococcal disease and associated morbidity and mortality  due to aging -related 
physiological changes in the respi[INVESTIGATOR_63465] [Drijkoningen, J. J 2014]
[Janssens, J. P. 2004] .For adults 65 ye ars of age and older, sequential administration of a 
PCV followed by  a pol ysaccharide pneumococcal vaccine is recommended by  [CONTACT_63505] I mmunization Practic es (ACIP) [Tomczy k, S., et al 2014] [Kobay ashi, M., et 
al 2015] . This recommendation is based on the observation that immune responses to 
seroty pes shared between the conjugate and polysaccharide vaccines are improved as 
compared to administration of either vaccine alone [Kobay ashi, M., et al 2015] . Sequential 
administration will provide additional protection against serotypes unique to 
PNEUMOVAX™23 (pneumococcal vaccine, poly valent (23 -valent), MSD ). This study  will 
also provide information on the persistence of the antibody  response to V114 one year after 
initial vaccination and will contribute to the overall safet y database and immunogenicit y 
profile of V114 to support initial licensure in adults.
This clinical study  is designed to evaluate th e safety, tolerability , and immunogenicity  of 
V114 compared with Prevnar 13™ . This study  will also describe the safet y of sequential 
administration of V114 or Prevnar 13™ followed by  [CONTACT_63506]™23 and evaluate the 
immune responses to the 15 seroty pes contai ned in V114 when PNEUMOVAX™23 is given 
approximately  12 months after receipt of either V114 or Prevnar 13™.
2.2 Background
2.2.1 V114 and Pneumococcal Disease 
Refer to the Investigator’s Brochure (IB) for V114 for more detailed background, including 
information on pneumococcal disease burden.
Streptococcus pneumoniae is a significant cause of disease worldwide, with clinical 
manifestations including pneumonia, meningitis, otitis media, sinusitis, and sepsis. Adults 
with comorbid conditions, in particular immunocompr omised individuals, have a higher 
incidence of invasive pneumococcal disease (IPD)morbidity  and mortality  in all age groups 
compared to adults without the comorbid conditions [Lexau, C. A., et al 2005] . 
  04Y2RW 
  05KFF2
PRODUCT: V114 26
PROTOCOL/AMENDMENT N O.:016-01
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
Currently  licensed pneumococcal conjugate vaccines (eg, Prevnar™, Sy nflorix™, and 
Prevnar 13™) were first implemented in infant immunization programs in many  countries 
worldwide. Prevnar™ was first licensed in 2000 and later replaced b y Prevnar 13™ in 2009
for the Europ eanUnion and in 2010 for the [LOCATION_002] . Although Prevnar 13™ is 
indicated for children and adults, Sy nflorix™ is only  indicated for children up to 5 y ears of 
age. Widespread use of PCVs has reduced the burden of pneumococcal disease caused by[CONTACT_63507] b y the vaccination 
programs and unvaccinated individuals from other age groups (herd protection) [Centers for 
Disease Control and Prevention 2008] [Ruckinger, S., et al 2009] [Farrell, D. J, et al 2007] 
[Pi[INVESTIGATOR_63466], Tamara, et al 2010] [L exau, C. A., et al 2005] [Metlay , J. P., et al 2006 ] [Whitney , 
Cynthia G., et al 2003] [Moore, M. R., et al 2015] [L epoutre, A., et al 2015] [Weiss, S., et al 
2015] [Martinelli, D., et al 2014] [Guevara, M., et al 2016] [Waight, P. A., et al 2015] 
[Jokinen, J., et al 2015] [Palmu, A. A., et al 2015] [Wagen voort, G. H., et al 2016] . 
Prevnar 13™ was also shown to be efficacious against vaccine -type nonbacteremic 
pneumococcal pneumon ia and IPD in adults ≥65 years of age [Bonten, M. J., et al 2015] . 
These stud y results were the basis of the recommendation from the ACI P for the sequential 
administration of Prevnar 13™ followed at least 12 months later by  [CONTACT_63506]™23 in 
adults ≥65 y ears of age [Tomczy k, S., et al 2014 ] [Kobay ashi, M., et al 2015] .
Although cases of IPD have decreased following implementation of PCVs, an increase in 
IPD caused b y serotypes not covered b y currently  available vaccines has been observed. 
V114 contains 2 additional serot ypes (22F , 33F) compared with Prevnar 13™. The selection 
of 22F and 33F was primarily based on epi[INVESTIGATOR_63467] [ADDRESS_68504] common seroty pe 
not included in Prevnar 13™ in adults ≥18 y ears of age, causing 13% of I PD cases. Seroty pe 
33F is associated with an additional 5% of I PD cases [Moore, M. R., et al 2015] . Data from 
the [LOCATION_008] also showed that , in 2013/2014, 22F and 33F arefrequent serot ypes in 
adults ≥65 y ears of age, accounting for approximately  10% and 4% of I PD cases in that age 
group , respectively  [Waight, P. A., et al 2015]. Data from [ADDRESS_68505] common seroty pes causing IPD 
[European Centre for Disease Prevention an d Control 2016] .
The serot ypes included in V114 will provide broad coverage of the leading serotypes 
associated with pneumococcal disease worldwide. V114 is designed to meet continuing 
medical and public health needs for PCVs globally, as well as to addres s the emergence of 
pneumococcal disease caused by  [CONTACT_63508]. V114 is 
designed to offer broader seroty pe coverage than Prevnar 13™ against pneumococcal disease 
in both pediatric and adult population s.
2.2.[ADDRESS_68506]: V114 27
PROTOCOL/AMENDMENT N O.:016-01
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
2.2.3 Information on Other Study -related Therapy
[IP_ADDRESS] Prevnar 13™
Refer to approved labeling for detailed background information on Prevnar 13™.
Prevnar 13™ contains all of the pneumococcal seroty pes included in Prevnar ™ (4, 6B, 9V, 
14, 18C, 19F, 23F) plus 6 additional seroty pes (1, 3, 5, 6A, 7F, and 19A).
The adult indication was approved based on immune responses elicited b y Prevnar 13™ in 
comparis on with PNEUMOVAX™23. A placebo -controlled clinical efficacy  trial 
(Community Acquired Pneumonia I mmunization Trial in Adults [CAPi[INVESTIGATOR_34172] ]) evaluated the 
efficacy  of Prevnar 13™ against pneumococcal pneumonia and IPD in immunocompetent 
adults ≥65 y ears of age. Results from CAPi[INVESTIGATOR_63468] 13™ was 45.6% (95%
confidence interval [ CI]:21.8% to62.5%) efficacious against vaccine -type nonbacteremic 
pneumococcal pneumonia and 75.0% ( 95% CI: 41.4% to90.8%) efficacious against vacci ne-
type IPD in adults ≥65 years of age [Bonten, M. J., et al 2015] .
Prevnar™ and Prevnar 13™ are also known as Prevenar™ and Prevenar 13™ in many  
countries outside of the [LOCATION_002]; these vaccines arereferred to as Prevnar™ and 
Prevnar 13™ throughout this document.
[IP_ADDRESS] PNEUMOVAX™23
Refer to approved labeling for detailed background information on PNEUMOVAX™23.
PNEUMOVAX™[ADDRESS_68507] important 
seroty pes causing diseas e in adults (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 
17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F). The formulation is not adjuvanted and no 
carrier protein is used.
In the [LOCATION_002], PNEUMOVAX™23 is recommended by  [CONTACT_63509] P for routine u se in 
immunocompetent adults ≥[ADDRESS_68508] 1 year after 
Prevnar 13™ [Kobay ashi, M., et al 2015] . It is also recommended for use in adults aged 19 
through 64 years of age with underly ing medical conditions that increase the risk for serious 
pneumococcal infection. These conditions include ,but are not limited to ,chronic heart 
disease, chronic lung disease (including chronic obstructive pulmonary disease, emph ysema, 
and ast hma), diabetes mellitus, alcoholism, chronic liver disease (including cirrhosis), and 
cigarette smoking [Centers for Disease Control and Prevention 2010] .
PNEUMOVAX™23 is also recommended in immunocompromised ad ults ≥19 years of age ; 
in this population, a dose of PNEUMOVAX™23 is recommended ≥8weeks following a 
dose of Prevnar 13™ [Kobay ashi, M., et al 2015] . Many  countries follow similar age -based 
and/or risk -based re commendations for the use of PNEUMOVAX™23 [Castiglia P. 2014] . 
  04Y2RW 
  05KFF2
PRODUCT: V114 28
PROTOCOL/AMENDMENT N O.:016-01
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
2.3 Benefit/Risk Asse ssment
It cannot be guaranteed that participants in clinical studies will directly  benefit from 
intervention during participation, as clinical studies are designed to provide information 
about the safet y and effectiveness of an investigational vaccine.
Approximately  50% of participants will receive Prevnar 13™, the standard of care, as the 
active comparator in this study . V114 is expected to provide comparable immune responses 
to Prevnar 13™ for the shared seroty pes while providing additional coverage for the 
2seroty pes (2 2F, 33F) unique to V114. I t is unknown if the investigational V114 will have 
the same benefit as Prevnar 13™. All participants will also receive PNEUMOVAX™[ADDRESS_68509] additional serotypes.
Additional details regarding specific benefits and risks for participants participating in this 
clinical study  may be found in the accompanyi ng IB and Informed Consent F orm ( ICF).
3 HYPOTHESIS, O BJECTIVES ,AND ENDPOINTS
The following objectives and endpoints will be evaluated in health y adults ≥50 y ears of age.
Objectives Endpoints
Primary
•Objective : To evaluate t he safet y and 
tolerability  of V114 compared with 
Prevnar 13™ with respect to the 
proportion of participants with adverse 
events (AEs).Following vaccination with V114 or 
Prevnar 13™:
Solicited injection -site AEs from Day  1 
through Day  5 postvaccination
Solicited sy stemic AEs from Day  1 
through Day  14 postvaccination
•Vaccine -related serious adverse events 
(SAEs ) from Day 1 to Month 12
•Objective : To evaluate the safet y and 
tolerability  of PNEUMOVAX™23 
administered 12 months following V114 
compared with PNEUMOVAX™23 
administered 12 months following 
Prevnar 13™ with respect to the 
proportion of participants with AEs.Following vaccination with 
PNEUMOVAX™23:
•Solicited injection -site AEs from Day  1 
through Day  5 postvaccination
•Solicited sy stemic AEs from Da y 1 
through Day  14 postvaccination
•Vaccine -related SAEs from Month [ADDRESS_68510]: V114 29
PROTOCOL/AMENDMENT N O.:016-01
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
Objectives Endpoints
•Objective : To evaluate the serot ype-
specific opsonophagocy tic activity  
(OPA) Geometric Mean Titers (GMTs) 
at 30 day s postvaccination with 
PNEUMOVAX™23 (Month 13) for 
partici pants administered V114 
compared with participants administered 
Prevnar 13™ 12 months before receipt 
of PNEUMOVAX™23 .Seroty pe-specific OPA responses for the 
15seroty pes in V114 at Month 13
Secondary
•Objective : To evaluate the serot ype-
specific Immunoglobulin G (IgG) 
Geometric Mean Concentrations 
(GMCs) at 30 day s postvaccination with 
PNEUMOVAX™23 (Month 13) for 
participants administered V114 
compared with participants administered 
Prevnar 13™ 12 months before receipt 
of PNEUMOVAX™23 .•Seroty pe-specific IgG responses for the 
15seroty pes in V114 at Month 13
•Objective : To evaluate the serot ype-
specific (1) OPA GMTs and IgG GMCs 
at 30 day s postvaccination (Day 30) and 
(2) Geometric Mean Fold Rises
(GMFRs )and propor tions of 
participants with a ≥4-fold rise from 
prevaccination (Day  1) to 30 day s 
postvaccination (Day 30) for both OPA 
and IgG responses for participants 
administered V114 and separately  for 
participants administered Prevnar 13™.  Seroty pe-specific OPA and IgG responses 
for the 15 serot ypes in V114 at Day 1 and 
Day 30
•Objective : To evaluate the serot ype-
specific (1) OPA GMTs and IgG GMCs 
at 12 months postvaccination 
(Month 12) and (2) GMFRs and 
proportions of participants with a ≥4-
fold rise from prevaccination (Day 1) to 
12 months postvaccination (Month 12) 
for both OPA and IgG responses for 
participants administered V114 and 
separately  for pa rticipants administered 
Prevnar 13™.Seroty pe-specific OPA and IgG responses 
for th e [ADDRESS_68511]: V114 30
PROTOCOL/AMENDMENT N O.:016-01
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
Objectives Endpoints
•Objective : To evaluate the serot ype-
specific (1) OPA GMTs and IgG GMCs 
at 30 day s postvaccination with 
PNEUMOVAX™23 (Month 13), (2) 
GMFRs and proportions of participants 
with a ≥4-fold rise from prevaccination 
(Day  1)to 30 day s postvaccination
(Month 13) with PNEUMOVAX™23 
for both OPA and IgG responses, and 
(3) GMFRs and proportions of 
participants with a ≥4-fold rise from 
prevaccination with 
PNEUMOVAX™23 (Month 12) to 30 
days postvaccination with 
PNEUMOVAX™23 (Month 13) for 
both OPA and IgG responses for 
participants administered V114 and 
separately  for pa rticipants administered 
Prevnar 13™ 12 months before receipt 
of PNEUMOVAX™23 .Seroty pe-specific OPA and IgG responses
for th e 15 serot ypes in V114 at Day 1, 
Month 12, and Month 13
4 S TUDY DESIGN
4.1 Overall Design
Approximately  600 individuals will be randomly  assigned in a 1:1 ratio to receive either 
V114 (300 participants) or Prevnar 13™ (300 participants) on Visit 1 (Day 1). 
Randomization will be stratified b y age (50 to 64 y ears, 65 to 74 y ears, and 75 y ears or older) 
and at least 50% of the participants will be 65 y ears of age or older. All participants will also 
receive a dose of PNEUMOVAX™23 at Visit 3 (Month 12).
Participants will be followed for local and s ystemic AEs through Day  14 following each 
vaccination. Information for SAEs and deaths, regardless of whether the events are 
considered to be vaccine -related b y the investigator, will be collected from the time consent 
is signed through completion of participati on in the study . An external Data Monitoring 
Committee (DMC) will conduct a periodic review of safet y and tolerability data for the adult 
V114 Phase [ADDRESS_68512]: V114 31
PROTOCOL/AMENDMENT N O.:016-01
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
Blood samples for immunogenicity  assay s will b e drawn immediatel y before V114 or 
Prevnar 13™ vaccination at Visit 1 (Day 1); at 30 day s postvaccination at Visit 2 (Day 30), 
immediately  before PNEUMOVAX™23 vaccination at Visit 3 (Month 12), and 30 day s 
postvaccination at Visit 4 (Month 13).
After completion of OPA and electrochemiluminescence (ECL )testing, serum samples will 
be stored to conduct an y additional study -related testing as required by [CONTACT_63510]. Leftover sera from the stud y ma y be used for the development and/or validation 
of pneumococcal assay s after completio n of all study -related immunogenicity  testing; this 
applies only  to sera received from randomized study  participants who provided consent for 
future biomedical research .
Specific procedures to be performed during the study , as well as their prescribed times and 
associated visit windows, are outlined in the SoA in Section 1.3. Details of each procedure 
are provided in Section 8.
4.2 Scientific Rationale for Study Design
This study  is conducted in a population (ie, healthy adults ≥50 y ears of age) at elevated risk 
for pneumococcal disease and associated morbidity and mortality  [Drijkoningen, J. J 2014] . 
For adults 65 years of age and older, sequential administration of a PCV followed by  a 
polysaccharide pneu mococcal vaccine is recommended by  [CONTACT_63511] [Tomczy k, S., et al 
2014] [Kobay ashi, M., et al 2015] . This recommendation is based on the observation that 
immune responses to seroty pes shared between the conjugate a nd poly saccharide vaccines 
are improved as compared to administration of either vaccine alone . The administration of 
PCV first followed by  [CONTACT_941] [ADDRESS_68513] [Kobay ashi, M., et al 2015] . Sequential administration will also provide additional 
protection against serot ypes unique to PNEUMOVAX™23. This study  will also pro vide 
information on the persistence of the antibody  response to V114 one y ear after initial 
vaccination and will contribute to the overall safety database and immunogenicity profile of 
V114 to support initial licensure in adults.
4.2.1 Rationale for Endpoints
[IP_ADDRESS] Immunogenicity Endpoints
Sera from participants will be used to measure vaccine -induced, serot ype-specific OPA and 
IgG responses for all 15 seroty pes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23 F, 
and 33F) i ncluded in V114 using the Multiplexed Opsonophagocy tic Assay  (MOPA) assay  
and pneumococcal electrochemiluminescence (PnECL ) assay .
Several studies have shown a positive correlation between serot ype-specific IgG antibody  
concentrations and OPA titers in children and adults [Centers for Disease Control and 
Prevention 2010] [Anttila, M., et al 1999] [Romero -Steiner, S., et al 1997] . OPA assesses 
levels of functional antibodies capable of opsonizing pneumococcal capsular polysaccharides 
forpresentation to phagocy tic cells for engulfment and subsequent killing, and therefore ,is  
  04Y2RW 
  05KFF2
PRODUCT: V114 32
PROTOCOL/AMENDMENT N O.:016-[ADDRESS_68514] I PD in adults. Note 
that no antibody  concentration or titer for either assay has been defined as the threshold value 
that correlates with protection in adults.
Details on the immunogenicity  endpoints evaluated in this study  can be found in 
Section 9.4.1.
[IP_ADDRESS] Safety Endpoints
The safet y endpoints evaluated in this study  were selected based on the product’ s safet y 
profile demonstrated in previous studies, published data from marketed PCVs, and feedback 
received from regulatory  agencies during product development. The electronic Vaccination 
Report Card (eVRC) used to record AEs during the postvaccination per iods, as defined in 
Section 8.1.9, was structured as recommended in the final Food and Drug Administration 
Patient Reported Outcome Guidance [U.S. Food and Drug Administration 2009] .
Details on the safet y endpoi nts evaluated in this study  can be found in Section 8.3.4 and 
Section 9.4.2.
Details on AEs, including definitions and reporting require ments, can be found in 
Appendix 3.
[IP_ADDRESS] Future Biomedical Research
The Sponsor will conduct future biomedical r esearch on specimens for which consent was 
provided during this study . This research may  include genetic anal yses (DNA), gene 
expression profiling ( ribonucleic acid [ RNA ]), proteomics, metabolomics (serum, plasma), 
and/or the measurement of other analy tes, depending on which specimens are consented for 
future biomedical r esearch.
Such research is for biomarker testing to address emergent questions not described elsewhere 
in the protocol (as part of the main study ) and will only  be conducted on specimens from 
appropriatel y consented participants. The objective of collecting/retaining specimens for 
future biomedical research is to explore and identify biomarkers that inform the scientific 
understanding of diseases and/or their therapeutic treatments. The overarching goal is to use 
such information to develop safer, more effective drugs/vaccines, and/or to ensure that 
participants receive the correct dose of the correct drug/vaccine at the correct time. The 
details of this future biomedical research substudy are presented in Appendix 6.
4.2.2 Rationale for the Use of Comparator
This study  utilizes Prevnar 13™ as the active comparator as this is the only PCV licensed in 
many  developed countries for use in adults. 
  04Y2RW 
  05KFF2
PRODUCT: V114 33
PROTOCOL/AMENDMENT N O.:016-01
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
Prevnar 13™ is approved for adults 18 y ears of age and older for the prevention of 
pneumococcal pneumonia and invasive disease caused by  13 Streptococcus pneumoniae
seroty pes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F).
Refer to approved labeling for detailed background information on Prevnar 13™.
4.[ADDRESS_68515] immune response.
The doses of Prevnar 13™ and PNEUMOV AX™[ADDRESS_68516] to follow -up (ie, the participant is unable to be contact[INVESTIGATOR_530] b y the 
investigator).
For purposes of analy sis and reporting, the overall study  ends when the Sponsor receives the 
last serology  assay result.
4.4.1 Clinical Criteria f orEarly Study Termination
There are no prespecified criteria for terminating the study  early.
5 STUDY POPULATION
Health y adult male s and females ( ≥50 y ears of age) will be enrolled in this study .
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.
5.1 Inclusion Criteria
Participants are eligible to be included in the study onl y if all o f the following criteria apply:
1.Be in good health. Any  underly ing chronic illness must be documented to be in stable 
condition.
Demographics
2.Participant is male or female ≥[ADDRESS_68517]: V114 34
PROTOCOL/AMENDMENT N O.:016-01
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
Female Participants
3.A female participant is eligible to participate if she is not pregnant (Appendix 5), not 
breastfeeding, and at least 1 of th e following conditions applies:
a.Not a woman of childbearing potential (WOCBP) as defined in Appendix 5.
OR
b.A WOCBP who agrees to use [ADDRESS_68518] dose of 
study  intervention .
Informed Consent
4.The participant provides written informed consent for the stud y. The participant may also 
provide consent for future biomedical research . However, the participant may  participate 
in the main study  without participating in future biomedical research .
5.2 Exclusion Criteria
Participants are excluded from the study if an y of the following criteria apply:
Medical Conditions
1.History  of IPD (positive blood culture, positive cerebrospi[INVESTIGATOR_63469], or positive 
culture at another sterile site) or known history  of other culture -positive pneumococcal 
disease within 3 y ears of Visit 1 (Day 1).
2.Known hy persensitivity  to any  component of pneumo coccal pol ysaccharide vaccine, 
pneumococcal conjugate vaccine, or an y diphtheria toxoid -containing vaccine.
3.Known or suspected impairment of immunological function including, but not limited to, 
a history  of congenital or acquired immunodeficiency , documen ted HIV infection, 
functional or anatomic asplenia, or history  of autoimmune disease (including but not 
limited to the autoimmune conditions outlined in the Investigator Trial File Binder for 
this study ).
4.Coagulation disorder contraindicating intramuscular vaccinations.
5.*Recent febrile illness (defined as oral or t ympanic temperature ≥100.4°F [≥38.0°C]; 
axillary or temporal temperature ≥99.4°F [≥37.4°C]; or rectal temperature ≥101.4°F 
[≥38.6°C]) or received antibiotic therapy for an y acute illness occurring within 72 hours 
before receipt of stu dy vaccine.
6.History of malignancy  ≤[ADDRESS_68519] vaccination 
at Visit 1 (Day 1).
Prior/Concomitant Therapy
8. Prior administration of any  pneumococcal vaccine or expected to receive any  
pneumococcal vaccine during the stud y outside of the protocol. 
  04Y2RW 
  05KFF2
PRODUCT: V114 35
PROTOCOL/AMENDMENT N O.:016-01
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
9.Received s ystemic corticos teroids ( prednisone equivalent of ≥20 mg/day ) for ≥[ADDRESS_68520] 30 day s before study  entry .
10.Received s ystemic corticosteroids exceeding ph ysiologic replacement doses 
(approximately  5 mg/ day prednisone equivalent) within 14 day s before vaccination.  
(Note : Topi[INVESTIGATOR_2855], ophthalmic, intra -articular or soft -tissue [eg, bursa, tendon steroid 
injections], and inhaled/nebulized steroids are permitted).
11.Receiving immunosuppressive therap y, including chemotherapeuti c agents used to treat 
cancer or other conditions, and interventions associated with organ or bone marrow 
transplantation, or autoimmune disease.  
12.*Received an y non -live vaccine within the 14 day s before receipt of anystudy  vaccine or 
is scheduled to rec eive any  non-live vaccine within 30 day s following receipt of any
study  vaccine. Exception : Inactivated influenza vaccine may  be administered but must be 
given at least [ADDRESS_68521] 15 day s after receipt of 
anystudy vaccine.
13.*Received an y live vaccine within [ADDRESS_68522] within 30 day s of receipt of study  vaccine. Autologous blood transfusions 
are not considered an exclusion criterion.
Prior/Concurrent Clinical Study Experience
15.Is currently  participating in or has participated in an interventional clinical study  with an 
investigational compound or device within 2 months of participating in this current stud y.
Other Exclusions 
16.Is breastfeeding
17.Is, at the time of signing informed consent, a user of recreational or illicit drugs or has 
had a recent history  (within the last y ear) of drug or alcohol abuse or dependence as 
assessed b y the stud y investigator .
18.Has history or current evidence of any  condition, therap y, lab abnormalit y or other 
circumstance that might expose the participant to risk by  [CONTACT_6231] , 
confound the results of the study , or interfere with the participant ’s participation for the 
full duration of the study .
19. Is or has an immediate family  member (eg, spouse, parent/legal guardian, sibling, or 
child) who is investigational site or Sponsor staff directly involved with this study.
For items with an asterisk (*), if the participant meets these exclusion criteria, the 
Day [ADDRESS_68523]: V114 36
PROTOCOL/AMENDMENT N O.:016-01
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
5.3 Lifestyle Considerations
No lifesty le restrictions are required.
5.4 Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study, but 
are not subsequently randomized in the study . A minimal set of screen failure information is 
required to ensure transparent reporting of screen failure participants to meet the 
Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to 
respond to queries from regulatory  authorities . Minimal information includes demograph y, 
screen failure details, eligibility criteria, and any AEs or SAEs meeting reporting 
requirements as outlined in the data entry guidelines.
5.5 Participant Replacement Strate gy
A participant who withdraws from the stud ywill not be replaced .
6 STUDY INTERVENTION
Study  intervention is defined as an y investigational intervention (s), marketed product(s), 
placebo, or medical device(s) intended to be administered to a study  participant according to 
the study  protocol.
Clinical supplies [V114, Prevnar 13™, PNEUMOVAX™23] will be packaged to support 
enrollment . Clinical supplies will be affixed with a clinical label in accordance with 
regulatory  requirements.
6.1 Study Intervention( s)Administered 
  04Y2RW 
  05KFF2
PRODUCT: V114 37
PROTOCOL/AMENDMENT N O.:016-01
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
The study intervention s to be used in this study are outlined inTable 1.
Table 1 Study  Intervention s
Arm 
NameArm Type Intervention Name [CONTACT_63563](s)Dosage 
Level(s)Route 
of 
AdminVaccination 
RegimenUse IMP/
NIMPSourcing
V114 Experimental V114 Biological/Vaccine Sterile 
suspension 
(prefilled 
syringe)Refer to IB 0.5 mL IM Single Dose 
at Visit 1 
(Day 1)Experimental IMP Central
PNEUMOVAX™23 Biological/Vaccine Sterile solution 
(prefilled 
syringe)Refer to 
product 
labeling0.5 mL IM Single Dose 
at Visit 3 
(Month 12)Experimental IMP Central
Prevnar 
13™Active 
ComparatorPrevnar 13™ Biological/Vaccine Sterile 
suspension 
(prefilled 
syringe)Refer to 
product 
labeling0.5 mL IM Single Dose 
at Visit 1 
(Day 1)Experimental IMP Central
PNEUMOVAX™23 Biological/Vaccine Sterile solution 
(prefilled 
syringe)Refer to 
product 
labeling0.5 mL IM Single Dose 
at Visit 3 
(Month 12)Experimental IMP Central
Admin=administration; IB =Investigator’s Brochure; IM =intramuscular; IMP = investigational medicinal product; NIMP = non-investigational medicinal 
product
The definition of IMP and NIMP is based on guidance issued by [CONTACT_63512]. Regional and/or country differences of the definition of IMP/NIMP 
may exist. In these circumstances, local legislation is followed.
All supplies indicated in Table 1will be provided per the “Sourcing ”column depending upon local country  operational requirements. 
Every  attempt should be made to source these supplies from a single lot/batch number
Refer to Section 8.1.[ADDRESS_68524]: V114 38
PROTOCOL/AMENDMENT N O.: 016 -01 
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
6.2 Preparation/Handling/Storage/Accountability
6.2.[ADDRESS_68525] be stored 
in a secure, environm entally  controlled, and monitored (manual or automated) area in 
accordance with the labeled storage conditions with access limited to the investigator and 
authorized site staff.
The investigator, institution, or the head of the medical institution (where a pplicable) is 
responsible for stud y intervention accountability , reconciliation, and record maintenance (ie, 
receipt, reconciliation, and final disposition records).
For all stud y sites, the local country Sponsor personnel or designee will provide appropri ate 
documentation that must be completed for drug accountability  and return, or local discard 
and destruction if appropriate. Where local discard and destruction is appropriate, the 
investigator is responsible for ensuring that a local discard/destruction procedure is 
documented.
The study  site is responsible for recording the lot number, manufacturer, and expi[INVESTIGATOR_63470] y purchased product (if applicable) as per local guidelines unless otherwise 
instructed by  [CONTACT_1034].
The investigator shall take responsibility  for and shall take all steps to maintain appropriate 
records and ensure appropriate supply, storage, handling, distribution, and usage of stud y 
intervention s in accordance with the protocol and any applicable laws and regulations.
6.3 Measures to Minimize Bias: Randomization and Blinding
6.3.1 Intervention Assignment
Treatment allocation/randomization will occur centrally using an interactive response 
technology  (IRT) s ystem. There are 2study  intervention arms. Participants will be assigned 
randomly  in a 1:1ratio to V114 or Prevnar 13™ , respectivel y. 
  04Y2RW 
  05KFF2
PRODUCT: V114 39
PROTOCOL/AMENDMENT N O.: 016 -01 
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
6.3.2 Stratification
Treatment allocation/randomization will be stratified according to the following factors:
Age at time of randomization :
1. Participants 50 to 64 years of age
2. Participants 65 to 74 y ears of age
3. Participants ≥[ADDRESS_68526] 50% of the participants will be ≥65 y ears of age.
6.3.3 Blinding
A double -blinding technique will be used. V114and Prevnar 13™ will be prepared and/or 
dispensed by  [CONTACT_63513]. The 
participant and the investigator who is involved in the clinical evaluation of the participants 
will remain blinded to the group assignments.
Because the V114 and Prevnar 13™ have a different appearance, a member of the study site 
staff will be unblinded for the purpose sof receiving, maintaining, preparing and/or 
dispensing, and administering the sestudy vaccine s.PNEUMOVAX™23 will also be 
prepare dand/or dispensed and administered by [CONTACT_63514] -label in this study .In order to avoid bias, the unblinded 
study person nelwill have no further contact [CONTACT_63515]-related 
procedures/assessments after administration of study  vaccines, which includes all safet y 
follow -up procedures . Additionally , blinded site personnel will not be present in the exam 
room when study  vaccines are administered. Contact [CONTACT_63516] .
Blinded site personnel will be responsible for all safet y and immunogenicity follow -up 
procedures after vaccine administration.
An unblinded Clinical Resea rch Associate will monitor vaccine accountability  at the study  
site. All other Sponsor personnel or delegate(s) and [COMPANY_006] Research Laboratories employ ees 
directly  involved with the conduct of this study  will remain blinded to the participant -level 
interven tion assignment.
See Section 8.1.12for a description of the method of unblinding a participant during the 
study  should such action be warranted.
6.4 Study Intervention Compliance
Interruptions from the protocol specified plan for V114 or Prevnar 13™vaccination at 
Visit 1 (Day 1) and PNEUMOVAX ™23 vaccination at Visit 3 (Month 12)require 
consultation between the investigator and the Sponsor and written documentation of the 
collaborative decision on participant management. 
  04Y2RW 
  05KFF2
PRODUCT: V114 40
PROTOCOL/AMENDMENT N O.: 016 -01 
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
6.5 Concomitant Therapy
Medications or vaccinatio ns specificall y prohibited in the exclusion criteria are not allowed
during the ongoing stud y. If there is a clinical indication for an y medication or vaccination 
specificall y prohibited, di scontinuation from study intervention may be required. The 
investigator should discuss any questions regarding this with the Sponsor Clinical Director. 
The final decision on any supportive therap y or vaccination rests with the investigator and/or 
the participant’ s primary  physician. However, the decision to continue the participant on 
study  intervention requires the mutual agreement of the investigator, the Sponsor, and the 
participant.
Listed below (items 1 to 4) are specific restrictions for concomitant therapy or vaccination 
during the course o f the study :
1.Any administration of a non -study  pneumococcal vaccine is prohibited during the stud y.
2.Live and non -live vaccines may  only  be administered prior to or following the receipt of 
study  vaccine according to the time frames specified in Exclusion C riteria (Section 5.2). 
Exception : Inactivated influenza vaccine may  be administered but must be given at least 
[ADDRESS_68527] 15 day s after receipt of any  study  
vaccine.
3.Participants should not receive s ystemic corticosteroids ( prednisone equivalent of ≥20 
mg/day  for ≥14 consecutive day s) starting from 30 day s prior to through 30 day s 
following vaccination. Note : Topi[INVESTIGATOR_2855], ophthalmic, intra -articular or soft -tissue (eg, bursa, 
tendon steroid injections), and inhaled/ne bulized steroids are permitted.
4.Participants should not receive s ystemic c orticosteroids exceeding phys iologic 
replacement doses (prednisone equivalent dose >5 mg/day ) within 14 day sbefore any  
vaccination. Note :Topi[INVESTIGATOR_2855], ophthalmic , intra -articular or soft-tissue (eg, bursa, tendon 
steroid injections), and inhaled/nebulized steroids are permitted.
Any deviation from the above requires consultation between the investigator and the Sponsor 
and written documentation of the collaborative decision on partici pant management.
6.5.1 Rescue Medications and Supportive Care
No rescue or supportive medications are specified to be used in this study.
6.6 Dose Modification (Escalation/Titration/Other)
No dose modification is allowed in this study .
6.[ADDRESS_68528]: V114 41
PROTOCOL/AMENDMENT N O.: 016 -01 
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
6.8 Clinical Supplies Disclosure
This study  is blinded but supplies are provided open label; therefore, an unblinded 
pharmacist or unblinded qualified study  site personnel will be used to maintain the blinding 
of study  staff who are directly  involved in the clinical evaluation of participants in the study . 
Study  intervention identity  (name, strength, or potency ) is included in the label text; r andom 
code/disclosure envelopes or lists are not provided.
The emergency  unblinding call center will use the intervention /randomization schedule for 
the study  to unblind participants and to unmask study  intervention identity . The emergency  
unblinding call center should only  be used in cases of emergency  (see Section 8.1. 12). In the 
event that the emergency unblinding call center is not available for a given site in this study , 
the central electronic intervention allocation/randomization sy stem (IRT) should be used to 
unblind participants and to unmask study  intervention identity . The Sponsor will not provide 
random code/disclosure envelopes or lists with the clinical supplies.
S
ee Section 8.1.[ADDRESS_68529] be collected through the participant’s last scheduled follow -
up, even if the participant has discontinued study intervention. Therefore, all participants 
who discontinue study  intervention prior to completion of the prot ocol-specified vaccinations
will still continue to participate in the study as specified in Section 1.3 and Section 8.12.3,
unless the participant withdraws consent (Section 7.2) .
Participants may discontinue study  intervention at any  time for any  reason or be d iscontinued 
from the study  intervention at the discretion of the investigator should an y untoward effect 
occur. In addition, a participant may  be discontinued from study  intervention by  [CONTACT_19419], the stud y plan is violated, or 
for administrative and/or other safet y reasons. Specific details regarding procedures to be 
performed at study  intervention discontinuation are provided inSection 8.1.[ADDRESS_68530] be discontinued from study intervention but continue to be monitored in 
the study  for an y of the following reasons:
•The participant requests to discontinue study  intervention. 
  04Y2RW 
  05KFF2
PRODUCT: V114 42
PROTOCOL/AMENDMENT N O.: 016 -01 
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
The participant has a medical condition or personal circumstance which, in the opi[INVESTIGATOR_19348]/or Sponsor, placed the participant at unnecessary risk from continued 
administration of study intervention.
•The participant has a confirmed positive urine or serum pregnancy  test before v accina tion 
with PNEUMOVAX™23 at Visit 3 (Month 12).
For participants who are discontinued from study  intervention but continue to be monitored 
in the study , see Section 1.3 and Section 8.12.3 for those procedures to be completed at each 
specified visit.
Discontinuation from study  intervention is “permanent.” Once a participant is discontinued, 
he/she shall not be allowed to restart stud y intervention .
7.[ADDRESS_68531] be withdrawn from the study  if the participant wit hdraws consent from the 
study .
If a participant withdraws from the study, they will no longer receive stud y treatment or be 
followed at scheduled protocol visits.
Specific details regarding procedures to be performed at the time of withdrawal from the 
study ,as well as specific details regarding withdrawal from future biomedical r esearch, are 
outlined in Section 8.1. 11.The procedures to be performed should a participant repeatedl y 
fail to return for scheduled visits and/or if the study site is unable t o contact [CONTACT_63517] 7.3.
7.[ADDRESS_68532] to Follow -up
If a participant fails to return to the clinic for a required study visit and/or if the site is unable 
to contact [CONTACT_2299], the following procedures are to be performed:
•The si te must attempt to contact [CONTACT_19423]. I f the 
participant is contact[INVESTIGATOR_530], the participant should be counseled on the importance of 
maintaining the protocol -specified visit schedule.
•The investigator or designee must make every  effort to regain contact [CONTACT_19424] (eg, telephone calls and/or a certified letter to the participant’s last 
known mailing address or locally  equivalent methods). These contact [CONTACT_63518]’s medical record.
•Note: A participant is not considered lost to follow -up until the last scheduled visit for the 
individual participant. The missing data for the participant will be managed via the 
prespecified statistical data handling and anal ysisguidelines. 
  04Y2RW 
  05KFF2
PRODUCT: V114 43
PROTOCOL/AMENDMENT N O.: 016 -01 
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
8 STUDY ASSESSMENTS AN D PROCEDURES
•Study  procedures and their timing are summarized in the SoA.
•Adherence to the stud y design requirements, including those specified in the SoA, is 
essential and required for study  conduct.
•The investigator is responsible for ensuring that procedures are conducted by  
[CONTACT_11399] y qualified or trained staff. Delegation of study site personnel responsibilities 
will be documented in the Investigator Study File Binder (or equivalent).
•All study -related medical dec isions must be made by  [CONTACT_19427] a qualified 
physician .
•All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility  criteria. The investigator will maintain a screening log to 
record de tails of all participants screened and to confirm eligibility  or record reasons for 
screening failure, as applicable.
•Additional evaluations/testing may  be deemed necessary  by [CONTACT_63519] y. In some cases, such evaluation/testing 
may be potentially  sensitive in nature (eg, HIV, Hepatitis C), and thus local regulations 
may require that additional informed consent be obtained from the participant. I n these 
cases, such evaluations/testing will be performed in accordance with those regulations.
Table 2shows the approximate blood volumes drawn b y study visit and by [CONTACT_63520]. The 
maximum amount of blood collected from each participant at each stud y visit willnot exceed 
50 mLand the total amount of blood for the entire study  will not exceed 170 mL . For those 
participants that consent to future biomedical research , an additional blood sample of 
approximately  8.5 mL will be taken.
Repeat or unscheduled samples may  be taken for safet y reasons or for technical issues with 
the samples.
Table 2 Approximate Blood Volumes Drawn b y Stud y Visit and by [CONTACT_63521] 1
Day 1Visit 2
Day 30Visit 3
Month 12Visit 4
Month 13
Blood parameter Approximate Blood Volume (mL)
Serum for immunogenicity assays (including retention 
serum) 40 mL 40 mL 40 mL 40 mL
Blood (DNA) for Future Biomedical Research 8.5 mL N/A N/A N/A
Expected t otal (mL) 48.5 mL 40 mL 40 mL 40 mL
DNA = deoxyribonucleic acid; N/A = not applicable 
  04Y2RW 
  05KFF2
PRODUCT: V114 44
PROTOCOL/AMENDMENT N O.: 016 -01 
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
8.1 Administrative and General Procedures
8.1.1 Informed Consent
The investigator or medically  qualified designee (consistent with local requirements) must 
obtain documented consent from each potential participant prior to participating in a clinical 
study or future biomedical r esearch .If there are changes to the participant’s status during the 
study  (eg, health or age of majority  requirements), the investigator or medically  qualified 
designee must ensure the appropriate consent is in place.
[IP_ADDRESS] General Informed Consent
Consent must be documented by  [CONTACT_2299]’s dated signature [INVESTIGATOR_2394] a consent form along 
with the dated signature [CONTACT_63564].
A cop y of the signed and dated consent form should be given to the participant before 
participation in the study .
The initial I CF, any  subsequent revised written ICF, and an y written information provided to 
the participant must receive the Institutional Review Board/Independent Ethics Committee’s 
(IRB/IEC’s )approval/favorable opi[INVESTIGATOR_63471]. The participant should be 
informed in a timely  manner if new information becomes available that may be relevant to 
the participant’s willingness to continue participation in the study . The communication of 
this information will be provided an d documented via a revised consent form or addendum to 
the original consent form that captures the participant’s dated signature.
Specifics about a stud y and the study population will be added to the consent form template 
at the protocol level.
The informe d consent will adhere to IRB/IEC requirements, applicable laws and regulations, 
and Sponsor requirements .
[IP_ADDRESS] Consent and Collection of Specimens for Future Biomedical Research
The investigator or medically  quali fied designee will explain the future biomedical research 
consent to the participant, answer all of his/her questions, and obtain written informed 
consent before performin g any procedure related to the future biomedical research sub study . 
A cop y of the informed consent will be given to the participant.
8.1.2 Inclusion/Exclusion Criteria
All inclusion and exclusion criteria will be reviewed by [CONTACT_63522] a qualified 
physician to ensure that the participant qualifies for the study .
If the participant meets any  of the Exclusion Criteria with an aster isk (*), Visit 1 (Day 1) may  
be rescheduled for a time when these criteria are not met. 
  04Y2RW 
  05KFF2
PRODUCT: V114 45
PROTOCOL/AMENDMENT N O.: [ADDRESS_68533] information (including direct 
telephone numbers) to be used in the event of an emergency . The investigator or qualified 
designee will provide the participant with a participant identification card immediately after 
the participant p rovides written informed consent. At the time of intervention
allocation/randomization, site personnel will add the intervention/randomization number to 
the participant identification card.
The participant identification card also contains contact [CONTACT_63523] a healthcare provider can obtain information about study 
intervention in emergency situations where the investigator is not available.
8.1.4 Medical Histo ry
A medical history  will be obtained by  [CONTACT_63524] 1 (Day 1). The participant’s medical history  for the 5 y ears prior to 
Visit 1 (Day 1) will be obtained to ensure that the participant satisfies the inclusion and 
exclusion criteria of the study .History  of tobacco use will also be collected for all 
participants .
8.1.5 Prior and Concomitant Medications Revi ew
[IP_ADDRESS] Prior Medications
The investigator or qualified designee will review and record prior vaccinations and 
medication staken b y the participant withi n [ADDRESS_68534] dose of study  vaccine at 
Visit 1 (Day 1).
[IP_ADDRESS] Concomitant Medications
The investigator or qualified designee will record medication, if an y, taken by [CONTACT_63525] y.
New and/or concomitant medications taken after Vi sit1 (Day 1) and non -study  vaccines 
received since Visit [ADDRESS_68535]: V114 46
PROTOCOL/AMENDMENT N O.: 016 -01 
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
Any participant who is screened multiple times will retain the ori ginal screening number 
assigned at the initial screening visit. Specific details on the screening/rescreening visit 
requirements are provided in Section 8.12.1.
8.1.7 Assignment of Treatment/Randomization Numb er
All eligible participants will be randomly allocated and will receive a 
treatment /randomization number. The treatment/randomization number identifies the 
participant for all procedures occurring after treatment allocation/randomization. Once a 
treatment /randomization number is assigned to a participant, it can never be re -assigned to 
another participant.
A single participant cannot be assigned more than 1 treatment /randomization number.
8.1.8 Study Intervention Administrati on
V114 or Prevnar 13™ will be administe red at Visit 1 (Day 1). PNEUMOVAX™23 will be 
administered at Visit 3 (Month 12).
Study vaccine sshould be removed from the refrigerator no more than 1 hour before 
vaccination. The time of removal and time of vaccination should be documented in the 
particip ant’s chart.
Unblinded study  personnel not otherwise involved in the conduct of the study  will prepare 
and administer V114, Prevnar 13™ ,or PNEUMOVAX™23 at the stud y site. 
PNEUMOVAX™[ADDRESS_68536] should use rapid, horizontal hand shaking for 5 to 
10 seconds while holding the sy ringe i n between the thumb and index finger until complete 
resuspension. This action should be repeated, as necessary . If appearance is otherwise, the 
vaccine should not be administered. The vaccine should not be used if the vaccine cannot be 
resuspended.
Study  personnel should follow the preparation and administration instructions for 
Prevnar 13™ and PNEUMOVAX™[ADDRESS_68537] labels.
Study  vaccine will be administered as a single 0.5 -mL intramuscular injection in the deltoid 
region of the participa nt’s arm. Vaccination information, such as Component I dentification 
Number and time of vaccination, must be recorded on the appropriate electronic case report 
form (eCRF )per the Data Entry  Guidelines.
All safet y and immunogenicity assessments will be conducted b y blinded personnel, and the 
participant will be blinded to the intervention (ie, V114 or Prevnar 13™) received. 
  04Y2RW 
  05KFF2
PRODUCT: V114 47
PROTOCOL/AMENDMENT N O.: 016 -01 
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
[IP_ADDRESS] Timing of Dose Administration
Vaccinations may  be administered at any  time of day , and without regard to timing of meals.
Each parti cipant's body  temperature must be taken before each vaccine administration. 
Individuals who present with fever (oral or t ympanic temperature ≥100.4°F [≥38.0°C]; 
axillary or temporal temperature ≥99.4°F [≥37.4°C]; or rectal temperature ≥101.4°F 
[≥38.6°C] ) will have the vaccination delayed until fever is resolved for at least 72 hours.
The collection of blood samples and administration of pregnancy tests (if applicable) must be 
done before each vaccine administration.
All participants will be observed for [ADDRESS_68538] be performed b y blinded site personnel for all study  
vaccines (Sectio n1.3 and Section 6.3.3 ).
8.1.[ADDRESS_68539]
The eVRC was developed to be administered el ectronically  via a hand -held device. This item 
was structured as recommended in the final Food and Drug Administration Patient Reported 
Outcome Guidance [U.S. Food and Drug Administration 2009] . The investigator or delegate 
will train the participant in the use of the eVRC at Visit 1 (Day 1) and Visit 3 (Month 12).
Temperatures, injection -site reactions, vaccine -specific complaints, other complaints or 
illnesses, and concomitant medications or vaccinations will b e recorded on the eVRC as 
described in Section 1.[ADDRESS_68540] (Day 15), Visit 2 (Day 30), 
Telephone Contact (Month 12.5), and Visit 4 ( Month 13).
For the AEs outlined above, the investigator will use the information provided by [CONTACT_63526], and verball y at the time of eVRC review, to apply the 
appropriate assessment of intensity  and toxicity  as d escribed in Appendix 3.
8.1.[ADDRESS_68541] Questionnaire provided b y the Sponsor. Data to be reported from this 
discussion will include SAEs and/or an y updates to concomitant medications, nonstudy  
vaccinations, and previously  reported safet y information.
8.1.[ADDRESS_68542]: V114 48
PROTOCOL/AMENDMENT N O.: 016 -01 
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
When a participant withdraws from participation in the study, all applicable activities 
scheduled for the final study  visit (Visit 4 [Month 13])should be performed (at the time of 
withdra wal). An y AEs that are present at the time of withdrawal should be followed in 
accordance with the safety requirements outlined in Section 8.4 .
[IP_ADDRESS] Withdrawal From Future Biomedical Resear ch
Participants may withdraw their consent for future biomedical r esear ch. Participants may  
withdraw consent at an y time by  [CONTACT_59554] [INVESTIGATOR_63472] . If 
medical records for the main study  are still available, the investigator will contact [CONTACT_63527] (clinical.speci [EMAIL_1249]). 
Subsequently ,the participant's consent for future biomedical r esearch will be withdrawn. A 
letter will be sent from the Sponsor to the investigator confirming the withdrawal. It is the 
responsibility  of the investigator to infor m the participant of completion of withdrawal. An y 
analyses in progress at the time of request for withdrawal or alread y performed prior to the 
request being received by [CONTACT_63528]. No new anal yses would be generated after the request is received.
In the event that the medical records for the main study  are no longer available (eg, if the 
investigator is no longer required b y regulatory authorities to retain the main study reco rds) 
or the specimens have been completel y anon ymized, there will no longer be a link between 
the participant’s personal information and their specimens. In this situation, the request for 
specimen withdrawal cannot be processed . 
8.1.12 Participant Blinding/Unbl inding
STUDY INTERVENT ION IDENT IFICATION INFORMAT ION IS TO BE UNMASKED 
ONLY IF NECESSARY FOR THE WELFARE OF THE PARTICIPANT. EVERY 
EFFORT SHOULD BE MADE NOT TO UNBLIND.
For emergency  situations where the investigator or medically  qualified designee (consistent 
with local requirements) needs to identify  the drug used by  a participant and /orthe dosage 
administered , he/she will contact [CONTACT_63529] t elephone and 
make a request for emergency  unblin ding. As requested by  [CONTACT_2697] y 
qualified designee the emergency  unblinding call center will provide the information to 
him/her promptly  and report unblinding to the Sponsor. Prior to contact[CONTACT_63530] r equest unblinding of a participant’s treatment assignment, the 
investigator who is a qualified phy sician should make reasonable attempts to enter the 
intensity /toxicity  grade of the AEs observed, the relation to study  intervention, the reason 
thereof , etc. , in the medical chart. If it is not possible to record this assessment in the chart 
prior to the unblinding, the unblinding should not be delay ed.
In the event that unblinding has occurred, the circumstances around the unblinding (eg, date, 
reason, and pe rson performing the unblinding) must be documented promptly , and the 
Sponsor Clinical Director notified as soon as possible. 
  04Y2RW 
  05KFF2
PRODUCT: V114 49
PROTOCOL/AMENDMENT N O.: [ADDRESS_68543], the principal investigator, site personnel, and 
Sponsor personnel may  be unblinded so that the appropriate follow -up medical care can be 
provided to the participant .
Participants whose treatment assignment has been unblinded by [CONTACT_2697] y 
qualified designee and/or nonstudy  treating ph ysician should continue to be monitor ed in the 
study .Participants may  receive PNEUMOVAX™23 at Visit 3 (Month 12)after a benefit/risk 
assessment and consultation between the investigator/delegate and Sponsor.
Additionally , the investigator or medically  qualified designee must go into the I RTsystem 
and perform the unblind in the I RT sy stem to update drug disposition. In the event that the 
emergency  unblinding call center is not available for a given site in this study , the IRT 
system should be used for emergency  unblinding in the event that t his is required for 
participant safety .
8.1.13 Calibration of Equipme nt
The investigator or qualified designee has the responsibility  to ensure that any  device or 
instrument used for a clinical evaluation/test during a clinica l study  that provides information 
about inclusion/exclusion criteria and/or safety  or efficacy  parameters shall be suitably  
calibrated and /ormaintained to ensure that the data obtained is reliable and/or reproducible. 
Documentation of equipment calibration must be retained as source document ation at the 
study  site.
8.2 Immunogenicity Assessmen ts
Sera from participants will be used to measure vaccine -induced OPA and IgG for serot ypes 
included in V114 and Prevnar 13™. These endpoints will be tested for all blood draws. 
Blood collection, storage and shipment instructions for serum samples will be provided in the 
operations/laboratory  manual.
The MOPA will be used for measuring OPA GMTs. Opsonization of pneumococci for 
phagocy tosis is an important mechanism by  [CONTACT_63531]. The OPA assay  is a useful tool for assessing the protective function 
of serot ype-specific antibodies and therefore ,the immunogenicit y of pneumococcal vaccine 
formulations.
Measurement of serot ype-specific IgG will be measured using the PnECL  v2.0 assay  to 
assess the concentration of binding antibodies to capsular pol ysaccharide of S. pneumoniae
for the serot ypes included in the study  vaccines .
8.2.1 Multiplex Opsonophagocytic Assa y (MOPA)
The MOPA, develo ped and published by  [CONTACT_63532] (Director of the United 
States W orld Health Organization pneumococcal serology reference laboratory and National 
Institutes of Health pneumococcal reference laboratories), is a multiplexed O PA assay  
capable of measuring [ADDRESS_68544]: V114 50
PROTOCOL/AMENDMENT N O.: 016 -01 
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
[Burton, Robert L . and Nahm, Moon H. 2006] . The OPA is an antibod y-mediated killing 
assay  that measures the abi lity of human serum to kill S. pneumoniae serot ypes with the help 
of complement and phagocytic effector cells. The ability  of the assay  to simultaneously  test 
4seroty pes/run reduces the amount of serum needed for testing. The assay  readout is the 
opsoniza tion index, which is the reciprocal of the highest dilution that gives ≥50% bacterial 
killing, as determined b y comparison to assay  background controls. MSD has developed and 
optimized the MOPA in a high throughput micro -colony  platform. The MOPA assay  forall 
15 V114 serot ypes has undergone validation. The validation study evaluated various 
performance parameters of the assay  including precision, relative accuracy/dilutional 
linearity , and specificity . The validation results were evaluated against pre -specified 
acceptance criteria for each of the parameters.
8.2.2 Electrochemiluminescence (ECL)
MSD has developed and optimized a multiplex, ECL -based detection method for the 
quantitation of IgG serotype -specific antibodies to the [ADDRESS_68545] pre -specified acceptance 
criteria for each of the parameters.
8.3 Safety Assessments
Details regarding specific safet y procedures/assessments to be performed in this study  are 
provided. The total amount of blood to be drawn over the course of the study (from prestud y 
to poststudy  visits), including approximate blood volumes drawn b y visit and by [CONTACT_63533] t ype 
per particip ant, can be found in Section 8 .
Planned time points for all safety assessments are provided in the SoA.
8.3.1 Physical Examinations
A complete ph ysical examination will be conducted by [CONTACT_63534] (consistent with local requirements) before vaccination at Visit 1 (Day 1). A 
directed ph ysical examination will be conducted by [CONTACT_63534] (consistent with local requirements) before vaccination at Visit 3 (Month 12).
Investigators should pay  special attention to clinical signs related to pr evious illnesses. 
  04Y2RW 
  05KFF2
PRODUCT: V114 51
PROTOCOL/AMENDMENT N O.: [ADDRESS_68546] consistent with local requirements (sensitive to at least 25 IU beta human 
chorionic gonadotropin [β-hCG ]) must be performed before vaccination at Visit 1 (Day 1) 
and Visit 3 (Month 12) in WOCBP as describe d in Section 1.3. Urine or serum tests can be 
used, and results must be negative before vaccination can occur.
8.3.3 Body Temperature Measurement
Each participant's body  temperature must be taken before vacci nation as described in 
Section 1.3.
Oral bod y temperat ures will also be documented by  [CONTACT_63535] -specified postvaccination follow -up period (Section 8.3.4).
For this study , any  oral or ty mpanic temperature ≥100.4°F (≥38.0°C), axillary  or temporal 
temperature ≥99.4°F (≥37.4°C) ,or rectal temperature ≥101.4°F (≥38.6°C) will be considered 
an AE of fever. All fevers must be reported Day  [ADDRESS_68547] be recorded on the appropriate eCRF.
Participants will use the eVRC (Section 8.1.9) to document the following information:
•Oral bod y temperatures measured Day 1 (day of vaccination) through Day 5 
postvaccina tion
•Solicited injection -site AEs (redness /erythema, swelling, and tenderness /pain ) Day  1 
through Day  5 postvaccination
•Solicited sy stemic AEs (muscle pain /myalgia , joint pain /arthralgia , headache, and 
tiredness /fatigue ) Day  1 through Day  14 postvaccinatio n
•Any other injection -site or sy stemic AEs Day 1 through Day  14 postvaccination
•Concomitant medications and nonstudy  vaccinations Day  [ADDRESS_68548]: V114 52
PROTOCOL/AMENDMENT N O.: 016 -01 
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
8.3.5 Clinical Laboratory Assessments
•Refer to Appendix [ADDRESS_68549] of clinical laboratory  tests to be performed and to the 
SoA for the timing and frequency .
•All protocol -required laboratory  assessments, as defined in Appendix [ADDRESS_68550] be 
conducted in accordance with the laboratory  manual and the SoA .
•If laboratory  values from nonprotocol specified l aboratory  assessments performed at the 
institution’s local laboratory  require a change in study  participant management or are 
considered clinically  significant by  [CONTACT_093] (eg, SAE or AE or dose 
modification), then the results must be recorded in t he appropriate CRF (eg, SL AB).
•For an y laboratory  tests with values considered clinically  significantl y abnormal during 
participation in the study  or within [ADDRESS_68551] dose of stud y intervention , 
every  attempt should be made to perform repeat assessments until the values return to 
normal or baseline or if a new baseline is established as determined b y the investigator .
8.4 Adverse Events (AEs), Serious Adverse Events (SAEs) ,and Other Reportable 
Safety Events
The definitions of an AE or SAE, as well as the method of recording, evaluating, and 
assessing causalit y of AE and SAE and the procedures for completing and transmitting AE, 
SAE, and other reportable safety event reports can be found in Appendix 3.
Adverse events, SAEs, and other reportable safety events will be reported by  [CONTACT_2299] 
(or, when appropriate, b y a caregiver orsurrogate).
The investigator and an y designees are responsible for detecting, documenting, and reporting 
events that meet the def inition of an AE or SAE, as well as other reportable safet y events. 
Investigators remain responsible for following up AE, SAEs, and other reportable safety 
events for outcome according to Section 8.4.3.
The investigator, who is a qualified ph ysician, will assess events that meet the definition of 
an AE or SAE as well as other reportable safet y events with respect to seriousness, 
intensity /toxicity  and causality .
8.4.1 Time Period and Frequency for Collecting AE, SAE ,and Other Reportable 
Safety Event Information
All AEs, SAEs, and other reportable safety events that occur after the consent form is signed 
but before allocation/randomization must be reported by  [CONTACT_63536] , or are the result of a proto col-specified 
intervention, including but not limited to washout or discontinuation of usual therap y, diet, 
placebo treatment, or a procedure. 
  04Y2RW 
  05KFF2
PRODUCT: V114 53
PROTOCOL/AMENDMENT N O.: [ADDRESS_68552] be reported b y the investigator from 
the day  of allocation/randomization to the first vaccination and from the day of each 
vaccination through [ADDRESS_68553] also be reported throughout the 
duration of the individual’s participation in the study, regardless of whether or not related to 
the Sponsor’ s product.
Additionally , any SAE brought to the attention of an investigator at an y time outside of the 
time period specified in the previous paragraph also must be reported immediatel y to the 
Sponsor if the event is either:
1.A death that oc curs prior to the participant completing the study .
OR
2.An SAE that is considered by  [CONTACT_19427] a qualified ph ysician to be vaccine 
related .
Investigators are not obligated to activel y seek AE or SAE or other reportable safet y events 
in former s tudy participants. However, if the investigator learns of an y SAE, including a 
death, at an y time after a participant has been discharged from the study, and he/she 
considers the event to be reasonabl y related to the study intervention or study  participati on, 
the investigator must promptly  notify  the Sponsor.
All initial and follow -up AEs, SAEs, and other reportable safety  events will be recorded and 
reported to the Sponsor or designee within the time frames as indicated in Table 3. 
  04Y2RW 
  05KFF2
PRODUCT: V114 54
PROTOCOL/AMENDMENT N O.: 016 -01 
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
Table 3 Reporting Time Periods and Time Frames for A dverse Events and Other 
Reportable Safet y Events
Type of Event Reporting Time 
Period:
Consent to 
Randomization/ 
AllocationReporting Time 
Period:
Randomization/ 
Allocation 
through Protocol -
Specified Follow -
up PeriodReporting Time Period:
After the Protocol 
Specified Follow -up 
PeriodTimefram e to 
Report Event 
and Follow -
up 
Information 
to 
SPONSOR :
Non-Serious Adverse 
Event (NSAE)Report if:
-due to protocol -
specified 
intervention
-causes exclusion
-participant is 
receiving placebo 
run-in or other 
run-in treatmentReport all Not required Per data entry 
guidelines
Serious Adverse Event 
(SAE)Report if:
-due to protocol -
specified 
intervention
-causes exclusion
-participant is 
receiving p lacebo 
run-in or other 
run-in treatmentReport all Report if:
-drug/vaccine related.
-any death until 
participant completion of 
study
(Follow  ongoing to 
outcome)Within 24 
hours of 
learning of 
event
Pregnancy/Lactation 
ExposureReport if:
-due to 
intervention
-causes exclusionReport all Previously reported –
Follow  to 
completion/termination; 
report outcomeWithin [ADDRESS_68554] for this study Not 
applicable
Cancer Report if:
-due to 
intervention
-causes exclusionReport all Not required Within 5 
calendar days 
of learning of 
event
Overdose Report if:
-receiving 
placebo run -in or 
other run -in 
medication Report all Not required Within 5 
calendar days 
of learning of 
event
8.4.2 Method of Detecting AE s, SAE s,and Other Reportable Safety Events
Care will be taken not to introduce bias when detecting AE and/or SAE and other reportable 
safet y events. Open -ended and nonleading verbal questioning of the participant is the 
preferred method to inquire about AE occurrence. 
  04Y2RW 
  05KFF2
PRODUCT: V114 55
PROTOCOL/AMENDMENT N O.: 016 -01 
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
8.4.3 Follow -up of AE, SAE ,and Other Reportable Safety Event Information
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
participant at subsequent visits/contacts. All AE, SAE, and other reportable safet y events 
including pregnancy  and exposure during breastfeeding, cancer, and overdose will be 
followed until resolution, stabilization, until the event is otherwise explained, or the 
participant is lost to follow -up (as defined in Section 7.3). In addition, the investigator will 
make every  attempt to follow all nonserious AEs that occur in randomized participants for 
outcome. Further information on follow -up procedures is given in Appendix 3 .
8.4.4 Regulatory Reporting Requirements for SAE
Prompt notification (within 24 hours) by  [CONTACT_63537] y of participants and the 
safety of a stud y intervention under clinical investigation are met.
The Sponsor has a legal responsibility  to notify  both the local regulatory  authority  and other 
regulatory agencies about the safet y of a stud y intervention under clinical investigation. All 
AEs will be reported to regulatory  authorities, IRB/IECs, and investigators in accordance 
with all applicable global laws and regul ations (ie, per ICH Topic E6 (R2 ) Guidel ines for 
Good Clinical Practice [GCP] ).
Investigator safety  reports must be prepared for suspected unexpected serious adverse 
reactions (S[LOCATION_003]R s) according to local regulatory  requirements and Sponsor policy  and 
forwarded to investigators as necessary .
An investigator who receives an investigator safety report describing an SAE or other 
specific safet y information (eg, summary or listing of SAE) from the Sponsor will file it 
along with the IB and will notify  the IRB/IEC, if appropriate according to local req uirements .
8.4.5 Pregnancy and Exposure During Breastfeeding
Although pregnancy  and infant exposure during breastfeeding are not considered AEs, an y 
pregnancy  or infant exposure during breastfeeding in a participant (spontaneously reported to 
the investigator or their designee) that occurs during the stud y are reportable to the Sponsor.
All reported pregnancies must be followed to the completion/termination of the pregnancy . 
Pregnancy  outcomes of spontaneous abortion, missed abortion, benign h ydatidiform mole, 
blighted ovum, fetal death, intrauterine death, miscarriage, and stillbirth must be reported as 
serious events (Important Medical Events). If the pregnancy continues to term, the outcome 
(health of infant) must also be reported.
8.4.6 Disease -related Events and/or Disease -related Outcomes Not Qualifying as 
AEs or SAEs
This is not applicable to this study . 
  04Y2RW 
  05KFF2
PRODUCT: V114 56
PROTOCOL/AMENDMENT N O.: [ADDRESS_68555] (ECI s)
There are no events of clinical interest for this study.
8.[ADDRESS_68556] be reported b y the investigator within 5 calendar day sto the 
Sponsor either by [CONTACT_26365]. Electronic reporting procedures can be f ound in 
the electronic data collection (EDC )data entry  guidelines. Paper reporting procedures can be 
found in the Investigator Trial File Binder (or equivalent ).
8.6 Pharmacokinetics
Pharmacokinetic parameters will not be evaluated in this study .
8.7 Pharmacodyna mics
Pharmacod ynamic parameters will not be evaluated in this study .
8.8 Future Biomedical Research Sample Collection
If the participant signs the future biomedical r esearch consent, the following specime ns will 
be obtained as part of future biomedical r esearch:
DNA for future research
Leftover stud y serum after completion of immunogenicity  testing stored for future 
research
8.[ADDRESS_68557]: V114 57
PROTOCOL/AMENDMENT N O.: 016 -01 
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
8.12 Visit Requirements
Visit requirements are outlined in Section 1.3. Specific procedure -related details are provided 
in Section 8.
8.12.1 Screening
Screening procedures will be conducted at Visit 1 (Day  1) as outlined in Section 1.3.
8.12.2 Treatment Period/Vaccination Visit
Requirements during the treatment period are outlined in Section 1.3.
8.12.3 Discontinued Participants Continuing to be Monitored in the Study
Aparticipant may discontinue from study  intervention (ie, vaccination) but continue to 
participate in subsequent protocol visits as outlined in Section 1.3, as long as the participant 
does not withdraw consent.  Protocol -specified activities, including blood draws for 
immunogenicit y assessments and AE monitoring, should occur at these visits.
9 STATISTICAL ANALYSIS PLAN
This section outlines the statistical analysis strategy and procedures for the study. Changes to 
analyses made after the protocol has been finalized, but prior to unblinding, will be 
documented in a supplemental Statistical Analy sis Plan and referenced in the Clinical Study  
Report (CSR) for the study . Post hoc exploratory  anal yses will be clearl y identified in the 
CSR.
9.1 Statistical Analysis Plan Summary
Key elements of the statistical anal ysis plan are summarized below; the comprehensive plan 
is provided in Sections 9.2 through 9.12 .
Study Design Overview A Phase 3, Multicenter, Randomized, Double -Blind, Active 
Com parator -Controlled Study to Evaluate the Safety, Tolerability, and 
Immunogenicity of V114 Follow ed by  [CONTACT_63491]™23 One Year Later in Healthy Adults 50 Years of 
Age or Older (PNEU -PATH)
Intervention Assignment Participants will be randomly assigned in a 1:1 ratio to V114 or 
Prevnar 13™, respectively. Randomization will be stratified into 
3groups according to the participant’s age at the time of 
randomization (50 to 64 years, 65 to 74 years, and ≥75 years) as 
described in Section 6.3.2 .
Analysis Populations Immunogenicity : Per Protocol (PP)
Safety : All Participants as Treated (A PaT) 
  04Y2RW 
  05KFF2
PRODUCT: V114 58
PROTOCOL/AMENDMENT N O.: 016 -01 
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
Prim ary Endpoint(s) Immunogenicity :
Serotype -specific OPA GMTs at 30 days postvaccination with 
PNEUMOVAX™23 (Month 13)
Safety : The follow ing analysis endpoints will be evaluated follow ing 
vaccination with V114 or Prevnar 13™ and follow ing 
PNEUMOVAX™23 :
Proportion of participants with solicited injection -site AEs 
(redness/erythema, swelling, tenderness/pain) from Day 1 through 
Day 5
Proportion of participants with solicited systemic AEs (muscle 
pain/myalgia, joint pain/arthralgia, headache, and 
tiredness/ fatigue) from Day 1 through Day 14 
Proportions of participants with vaccine -related SAEs in the 
12months following V114 or Prevnar 13™ administration (from 
Day 1 to Month 12)and in the 30 days following administration of 
PNEUMOVAX™23 (Month 12 to Month 13) will also be 
evaluated .
Key Secondary Endpoints Immunogenicity :
Serotype -specific IgG GMCs at 30 days postvaccination with 
PNEUMOVAX™23 (Month 13)
Serotype -specific OPA GMTs and IgG GMCs at 30 days 
postvaccination with V114 o r Prevnar 13™ (Day 30)
Serotype -specific OPA GMTs and IgG GMCs at 12 months 
postvaccination with V114 or Prevnar 13™ (Month 12)
Statistical Methods for Key 
Immunogenicity AnalysesImmunogenicity analyses will be conducted for each of the 
15pneumococcal serotypes in V114 separately. To address the 
primary immunogenicity objective, the serotype -specific OPA GMTs 
at 30 days postvaccination with PNEUMOVAX™23 (Month 13) w ill 
be compared betw een vaccination groups through the estimation of 
serotype -specific OPA GMT ratios for e ach of the 15 serotypes in 
V114. Estimation of the OPA GMT ratios and computation of the 
corresponding 95% CIs will be calculated using a constrained 
longitudinal data analysis (cLDA) method [Liang, K -Y and Zeger, S. 
L. 2000] . The OPA GMT ratios at 30 days postvaccination with V114 
or Prevnar 13™ (Day 30) and at 12 months postvaccination with V114 
or Prevnar 13™ (Month 12) will be evaluated within the same cLDA 
model.
A similar statistical approach will be used t o evaluate the IgG GMCs at 
30 days postvaccination with V114 or Prevnar 13™ (Day 30), at 12
months postvaccination with V114 or Prevnar 13™ (Month 12), and at 
30 days postvaccination with PNEUMOVAX™23 (Month 13) for 
participants administered V114 compared with participants 
administered Prevnar 13™ .
Statistical Methods for Key 
Safety AnalysesP-values (Tier 1 endpoints) and 95% CIs (Tier 1 and Tier 2 endpoints) 
will be provided for betw een-group differences in the percentage of 
participants with events; the se analyses will be performed using the 
unstratified Miettinen and Nurminen method [Miettinen, O. and 
Nurminen, M. 1985] . 
  04Y2RW 
  05KFF2
PRODUCT: V114 59
PROTOCOL/AMENDMENT N O.: [ADDRESS_68558] to enable a benefit -risk assessment.
Multiplicity No adjustment will be made for multiplicity .
Sample Size and Power Immunogenicity :
This study will randomize approximately 300 participants into the 
V114 group and 300 participants into the Prevnar 13™ group .It is 
assumed that approximately 240 participants p er group will be 
evaluable for the PP immunogenicity analyses at Month 13 (80% 
evaluability rate) . There are no hypotheses to be evaluated . 
Section 9.9.1 provides information about the expected variability of 
the GMT ratios given the sample size.
Safety :
Section 9.9.2 provides information about the ability of this study to 
estimate the incidence of AEs within the V114 group as w ell as 
diffe rences between V114 and Prevnar 13™.
9.2 Responsibility for Analyses/In -house Blinding
The statistical anal ysis of the data obtained from this study  will be the responsibility  of the 
Clinical Biostatistics department of the Sponsor .
This study  will be conducted as a double -blind study  under in -house blinding procedures. 
The official, final d atabase will not be unblinded until medical/scientific review has been 
performed, protocol deviations have been identified, and data have been declared final and 
complete.
The Clinical Biostatistics department will generate the randomized allocation schedu le(s) for 
study  intervention assignment. Randomization will be implemented using an IRT.
Blinding issues related to the planned interim analyses are described in Section 9.7.
9.3 Hypotheses/Estimation
Objectives of the stud y are stated in Section 3. This is an estimation study  and no formal 
hypothes is testing will be performed.
9.4 Analysis Endpoints
Immunogenicit y and safety analy sis endpoints that will be evaluated for within - and/or 
between -intervention differences are listed below. 
  04Y2RW 
  05KFF2
PRODUCT: V114 60
PROTOCOL/AMENDMENT N O.: 016 -01 
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
9.4.1 Immunogenicity Endpoints
A de scription of immunogenicity  assessments is contained in Section 8.2.
Immune responses will be measured for each of the following serot ypes contained in V114: 
1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F.
The primary  immunogenicity  analy sis endpoint is the serot ype-specific OPA GMTs at 
30days postvacci nation with PNEUMOVAX™23 (Month 13)
.
The secondary  analy sis immunogenicit y endpoints include:
Seroty pe-specific IgG GMCs at 30 day s postvaccination with PNEUMOVAX™23 
(Month 13)
Seroty pe-specific OPA GMTs and IgG GMCs at 30 day s postvaccination with V114 
or Prevnar 13™ (Day 30)
Seroty pe-specific OPA GMTs and IgG GMCs at 12 months postvaccination with 
V114 or Prevnar 13™ (Month 12)
Seroty pe-specific GMFRs and proportion sof participants with a ≥4-fold rise from 
prevaccination (Day 1) to 30 day s postvaccination with V114 or Prevnar 13™
(Day 30) for both OPA and IgG responses
Seroty pe-specific GMFRs and proportions of participants with a ≥4-fold rise from 
prevaccination (Da y1) to 12 months postvaccination with V114 or Prevnar 13™
(Month 12) for both OPA and IgG responses
Seroty pe-specific GMFRs and proportions of participants with a ≥4-fold rise from 
prevaccination (Day 1) to 30 day s postvaccination with PNEUMOVAX™23 
(Month 13) for both OPA and IgG responses
Seroty pe-specific GMFRs and proportions of participants with a ≥4-fold rise from 
prevaccination with PNEUMOVAX™23 (Month 12) to 30 day s postvaccination with 
PNEUMOVAX™23 (Month 13)for both OPA and IgG responses
9.4.2 Safety E ndpoints
A description of safet y measures is contained in Sections 8.3 and 8.4. The anal ysis of safety  
results is described in Section 9.6.2.
Safety  and tolerability  will be assessed b y clinical review of all relevant parameters including 
adverse events an d postvaccination temperature measurements following V114 or 
Prevnar 13™ and following PNEUMOVAX™23 (separately ).
The safet y analysis endpoints include :
Proportion of participants with solicited injection -site AEs (redness/ery thema, 
swelling, tenderness/pain) from Day  [ADDRESS_68559]: V114 61
PROTOCOL/AMENDMENT N O.: 016 -01 
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
Proportion of participants with solicited sy stemic AEs (muscle pain/m yalgia, joint 
pain/arthralgia, headache, and tiredness/fatigue) from Day 1 through Day 14 
postvaccination 
Proportions of partici pants with the broad AE categories consisting of an y AE, a 
vaccine -related AE, a SAE, an AE which is both vaccine -related and serious, and 
discontinuation due to an AE, and the proportion of participants who died
Proportion of participants with maximum tem perature measurements meeting the 
Brighton Collaboration cut points from Day 1 through Day  5 postvaccination
9.5 Analysis Populations
9.5.1 Immunogenicity Analysis Populations
The Per -Protocol (PP) population will serve as the primary  population for the anal ysis of 
immunogenicit y data in this study .The PP population consists of all randomized participants 
withoutdeviations from the protocol that may  substantially  affect the results of t he 
immunogenicit y endpoint. Potential d eviations that may  result in the exclusio n of a 
participant from the PP population for all immunogenicity  analyses include:
Failure to receive an y study  vaccine at Visit 1(Day 1)
Failure to receive correct clinical material as per randomiz ation schedule (ie, 
participants who were cross -treated )
Receipt of a prohibited medication or prohibited vaccine prior to study vaccination
Additional potential deviations that may  result in the exclusion of a participant from the PP 
population for specific immunogenicit y analyses (depending on the time point) include:
Failure to receive PNEUMOVAX™23
Receipt of a prohibited medication or prohibited vaccine prior to a blood sample 
collection 
Collection of a blood sample outside of the pre -specified window (as described in 
Section 1.3)
The final determination on protocol deviations, and thereb y the composition of the PP
population, will be made prior to the final unblinding of the database. Participants will be 
included in the vaccination group to which they  are randomized for the analy sis of 
immunogenicit y data u sing the PPpopulation .
A supportive anal ysis using the Full Anal ysis Set (FAS) population will also be performed 
for the primary  immunogenicity  endpoint (s). The FAS population consists of all randomized 
participants who received at least [ADDRESS_68560]: V114 62
PROTOCOL/AMENDMENT N O.: 016 -01 
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
9.5.2 Safety Analysis Populations
Safety  anal yses will be conducted in t he All Participants as Treated (APaT) population, 
which consists of all randomized pa rticipants who received at least [ADDRESS_68561] study  
vaccination; such participants will be included in the group corresponding to the study 
vaccination actually  received.
At least 1 temperature measurement obtained subsequent to study  intervention is required for 
inclusion in the analy sis of temperature.
9.6 Statistical Methods
Statistical testing and inference for immunogenicity  and safet y anal yses are descr ibed in 
Section 9.6.1 and Section 9.6.2, respectively. Unless otherwise stated, all statistical tests will 
be conducted at the α=0.05 (2 -sided) level. Section 9.6.[ADDRESS_68562] ess the primary  immunogenicity  objective, the seroty pe-specific 
OPA GMTs at 30 day s postvaccination with PNEUMOVAX™23 (Month 13) will be 
compared between vaccination groups through the estimation of serot ype-specific OPA GMT 
ratios for each of the 15 serot ypes in V114. Estimation of the OPA GMT ratios and 
computation of the corresponding 95% CIs will be calculated using a cLDA method 
proposed b y Liang and Zeger [Liang, K -Y and Zeger, S. L . 2000] utilizing data fr om both 
vaccination groups. In this model, the response vector consists of the log -transformed 
baseline (Day  1) and post baseline ( Day 30, Month 12, and Month 13 ) antibody  titers. The 
repeated measures model will include terms for vaccination group, time, the interaction of 
time-by-vaccination group (with a restriction of the same baseline mean across groups), age 
stratum (ie, 50 to 64 y ears, 65 to 74 y ears, and ≥75 y ears) at Day 1,and age stratum -by-time 
interaction. This model will allow for different baseline means for each age stratum, but 
restrict the baseline mean within each age stratum to be the same for both vaccination groups. 
An unstructured covariance matrix will be used to model the correlation among repeated 
measurements. The Kenward -Roger a djustment will be used with restricted (or residual) 
maximum likelihood to make proper statistical inference. The OPA GMT ratios at  30 day s 
postvaccination with V114 or Prevnar 13™ (Day 30) and at 12 months postvaccination with 
V114 or Prevnar 13™ (Month 12) will be evaluated within the same model. This model 
allows the inclusion of participants who are missing either the baseline or post -baseline 
measurements, thereb y increasing eff iciency . 
  04Y2RW 
  05KFF2
PRODUCT: V114 63
PROTOCOL/AMENDMENT N O.: 016 -01 
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
A similar statistical approach will be used to evaluate the IgG GMCs at 30 day s 
postvaccination with V114 or Prevnar 13™ (Day 30), at 12 months postvaccination with 
V114 or Prevnar 13™ (Month 12), and at 30 days postvaccination with PNEUMOVAX™23 
(Month 13) for participants administered V114 compared with participants administered 
Prevnar 13™.
Descriptive statistics with point estimates and within -group 95% CIs will be provided fo r all 
immunogenicit y endpoints. For the continuous endpoints, the poin t estimates will be 
calculated b y exponentiating the estimates of the mean of the natural log values and the 
within -group CIs will be derived by [CONTACT_63538] t -distribution. For the dichotomous e ndpoints, the within -group CIs will 
be calculated using the exact method for a single binomial proportion [Collett, D. 1999] .
Reverse Cumulative Distribution Curves for both OPA titers and IgG concentrations wil l be 
graphicall y displayed b y seroty pe at each of the following time points :  Day 30, Month 12, 
and Month 13.
A detailed analy sis strategy  for key immuno genicity  endpoints is listed in Table 4.
Table 4 Analy sis Strategy  for Immunogenicit y Variables
Endpoint/Variable
(Description, Time Point)Primary vs. 
Supportive 
Approach†Statistical 
Method‡Analysis 
PopulationMissing Data 
Approach
Prim ary Endpoint
OPA GMTs atMonth 13P cLDA§
(estimate, 95%
CI)PP
Model -based
S FAS
Secondary Endpoints
IgG GMCs atMonth 13 PcLDA§
(estimate, 95%
CI)PP Model -based
OPA GMTs and IgG GMCs atDay 30 PcLDA§
(estimate, 95%
CI)PP Model -based
OPA GMTs and IgG GMCs atMonth 12 PcLDA§
(estimate, 95%
CI)PP Model -based
OPA GMTs and IgG GMCs atDay 30 PDescriptive 
Statistics
(estimate, 95%
CI)PPMissing data 
will not be 
imputed
OPA GMTs and IgG GMCs atMonth 12 PDescriptive 
Statistics
(estimate, 95%
CI)PPMissing data 
will not be 
imputed
OPA GMTs and IgG GMCs atMonth 13 PDescriptive 
Statistics
(estimate, 95%
CI)PPMissing data 
will not be 
imputed 
  04Y2RW 
  05KFF2
PRODUCT: V114 64
PROTOCOL/AMENDMENT N O.: 016 -01 
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
Endpoint/Variable
(Description, Time Point)Primary vs. 
Supportive 
Approach†Statistical 
Method‡Analysis 
PopulationMissing Data 
Approach
GMFRs and %s of participants with a ≥4-fold 
risefrom Day 1 to Day 30 for both OPA and 
IgG responsesPDescriptive 
Statistics
(estimate, 95%
CI) PPMissing data 
willnot be 
imputed
GMFRs and %s of participants with a ≥4-fold 
risefrom Day 1 to Month 12 for both OPA 
and IgG responsesPDescriptive 
Statistics
(estimate, 95%  
CI)PPMissing data 
will not be 
imputed
GMFRs and %s of participants with a ≥4-fold 
risefrom Day 1 to Month 13 for both OPA 
and IgG responsesPDescriptive 
Statistics
(estimate, 95%
CI)PPMissing data 
will not be 
imputed
GMFRs and %s of participants with a ≥4-fold 
risefrom Month 12 to Month 13 for both 
OPA and IgG responsesPDescriptive 
Statistics
(estimate, 95%
CI)PPMissing data 
will not be 
imputed
†P=Primary approach; S=Supportive approach.
‡Statistical models are described in further detail below:
§Constrained longitudinal data analysis (cLDA) model with terms for vaccination group, time, the 
interaction of time -by-vaccination group, age stratum, and the interaction of age stratum -by-time.
CI = c onfidence interval ; FAS = Full Analysis Set; GMC = Geom etric Mean Concentration; GMFR =
Geom etric Mean Fold Rise; GMT = Geometric Mean Titer; IgG = Immunoglobulin G; OPA =
Opsonophagocytic Activity; PP =PerProtocol
9.6.2 Statistical Methods for Safety Analyses
Safet y and tolerability  will be assessed b y clinical review of all relevant parameters including 
AEs and postvaccination temperature measurements .
The anal ysis of safet y results following each vaccination will f ollow a tiered approach 
(Table 5). The tiers differ with respect to the anal yses that will be performed. AEs (specific 
terms as well as s ystem organ class terms) are either pre -specified as “Tier 1” endpoints, or 
will be classified as belonging to "Tier 2" or "Tier 3" based on the number of events 
observed.
Tier [ADDRESS_68563] that are identified a priori constitute 
“Tier 1” safet y endpoints that will be subject to inferential testing for statistical significance 
with p -values and 95% CIsto be provided for between -group differences in the proportion of 
participants with events; these anal yses will be perf ormed using the unstratified Miettinen 
and Nurminen (M&N) method [Miettinen, O. and Nurminen, M. 1985] , an unconditional, 
asymptotic method . For this protocol, solicited injection -site AEs (redness/ery thema, 
swelling, tenderness/pain) from Day  1 through Day  5 postvaccination and solicited sy stemic 
AEs (muscle pain/m yalgia, joint pain/arthralgia, headache, and tiredness/fatigue) from Day [ADDRESS_68564]: V114 65
PROTOCOL/AMENDMENT N O.: 016 -01 
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
Tier 2 Events
Tier 2 parameters will be assessed via point estimates with 95% CIs provided for differences 
in the proportion of participants with events (also via the unstratified M&N method 
[Miettinen, O. and Nurminen, M. 1985] ).
Membership in Tier [ADDRESS_68565] 4 events was chosen because the 95% CI for the between -
group difference in percent incidence will always include zero whe n vaccination groups of 
equal size each have less than 4 events and thus would add little to the interpretation of 
potentially  meaningful differences. Because man y 95% CI s for Tier [ADDRESS_68566]: V114 66
PROTOCOL/AMENDMENT N O.: 016 -01 
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
Table 5 Analy sis Strategy for Safety  Parameters Following Each Vaccination
Safety Tier Safety Endpoint p-Value95% CI for 
Betw een-
Group 
Com parisonDescriptive 
Statistics
Tier 1 Injection -site redness /erythema (Days 1 to 5) X X X
Injection -site swelling (Days 1 to 5) X X X
Injection -site tenderness /pain (Days 1 to 5) X X X
Muscle pain /myalgia (Days 1 to 14) X X X
Joint pain /arthralgia (Days 1 to 14) X X X
Headache (Days 1 to 14) X X X
Tiredness /fatigue (Day s 1 to 14) X X X
Tier 2 Any AE†X X
Any v accine -related AE†X X
Any SAE†X X
Any vaccine -related SAE†X X
Discontinuation due to AE†X X
Death†X X
Maximum temperature measurements meeting 
the Brighton Collaboration cut points
(Day s 1 to 5) X X
Specific AEs by[CONTACT_3592]‡(incidence ≥4 of 
participants in one of the vaccination groups)X X
Tier 3 Specific AEs by[CONTACT_3592]‡(incidence <4 of 
participants in all of the vaccination groups)X
†These endpoints are broad adverse event categories. For example, descriptive statistics for the 
safety endpoint of “Any AE” will provide the number and percentage of participants with at least 
one AE. 
‡Includes only those endpoints not pre -specified as Tier 1 or not already pre -specified as Tier 2
endpoints.
AE=adverse event; CI = confidence interval; PT=preferred term; SAE =serious adverse event; 
SOC = system organ class; X = results will be provided.
The anal ysis of safet y parameters will be evaluated at two separate time points:  (1) 
following administration of V114 or Prevnar 13™ and (2) following administration of 
PNEUMOVAX™23. Descriptive summaries of AEs following administration of V114 or 
Prevnar 13™ will include non -serious adverse even ts (NSAEs) within 14 day s of vaccination 
and SAEs occurring Day 1 through Month 12 (before vaccination with PNEUMOVAX™23). 
Descriptive summaries of AEs following administration of PNEUMOVAX™23 will include 
NSAEs within 14 day s of vaccination and SAEs occur ring Month 12 (Day 1 relative to 
vaccination with PNEUMOVAX™23) through Month 13 (Day 30 relative to va ccination 
with PNEUMOVAX™23).
Safety  anal yses will be based on the observed data (ie, with no imputation of missing data). 
  04Y2RW 
  05KFF2
PRODUCT: V114 67
PROTOCOL/AMENDMENT N O.: 016 -01 
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
9.6.3 Demographic and Baseline Char acteristics
The comparability  ofthe vaccination groups for each relevant demographic and baseline 
characteristic will be assessed b y the use of summary  tables . No statistical hy pothesis tests 
will be performed on these characteristics. The number and percentage of participants 
screened and randomized a nd the primary  reasons for screening failure and discontinuation 
will b e display ed. Demographic variables (eg, age , race, and gender ), baseline characteristics, 
prior and concomitant vaccinations and therapi[INVESTIGATOR_63473] b y descriptive statistics or categorical tables .
9.[ADDRESS_68567] to enable a benefit -
risk assessment .
Study  enrollment is likely  to be ongoing at the time of any  interim analy ses. Blinding to 
intervention assignment will be maintained at all investigational sites. The results of interim 
analyses will not be shared with the investigators prior to the completion of the study. 
Participant -level unblinding will be restricted to an external unblinded statistician performing 
the interim anal ysis.
The DMC will serve as the primary  reviewer of the results of the safet y interim anal yses and 
will make recommendations for discontinuation of the study  or protocol modifications to an 
executive committee of the Sponsor (see Appendix 1 for details on the Committees Structure 
for this study ). If the DMC recommends modifications to the design of the protocol or 
discontinuation of the study , this executive committee (and potentiall y other limited Sponsor
personnel) may  be un blinded to results at the intervention level in order to act on these 
recommendation s. The extent to which individuals are unblinded with respect to results of 
interim analy ses will be documented by  [CONTACT_63539]. Additional logistical 
details will be provided in the DMC Charter.
Intervention -level results from the safety  interim analy sis will be provided by  [CONTACT_63540]. Prior to final stu dy unblinding, the unblinded statistician will not be 
involved in any  discussions regarding modifications to the protocol, statistical methods, 
identification of protocol deviations, or data validation efforts after the interim analyses.
9.[ADDRESS_68568]: V114 68
PROTOCOL/AMENDMENT N O.: 016 -01 
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
9.9 Sample Size and Power Calculations
9.9.1 Sample Size and Power for Immunogenicity Analyses
This is a descriptive study. This study  will randomize approximately  300participants into the 
V114 group and 300 participants into the Prevnar 13™ group . It is assumed that 
approximately  240 participants p er vaccination group will be evaluable for PP 
immunogenicit y anal yses at Month 13 (based on a 80% evaluability  rate) . 
The width of the 95% CIs for the serot ype-specific OPA GMT rat ios depend on the sample 
size, variability  of the natural log concentrations, and the magnitude of the GMT ratio. In 
Table 6, 95% CIs for various hy pothetical Month [ADDRESS_68569] deviation estimates for the natural log tit ers are display ed.
Table 6 95% CI s for Vary ing Hypothetical OPA GMT Ratios (V114/Prevnar 13™) and 
Vary ing Standard Deviations with [ADDRESS_68570] Deviation 
of Natural Log 
Titers†Seroty pe-specific GMT Ratios (V114/Prevnar 13™)†
0.8 1.0 1.2 1.5
1.5 (0.61, 1.05) (0.76, 1.31) (0.92, 1.57) (1.15, 1.96)
2.0 (0.56, 1.15) (0.70, 1.43)  (0.84, 1.72) (1.05, 2.15)
2.5 (0.51, 1.25) (0.64, 1.57) (0.77, 1.88) (0.96, 2.35)
†The estimates of the standard deviation and GMT ratio are representative of those observed in V114 -006
CI=c onfidence interval; OPA = opsonophagocytic activity ; GMT= Geometric Mean Titer
9.9.[ADDRESS_68571] 1SAE in this study  depends on the number of 
participants vaccinated and the underl ying incidence of participants with a SAE in the study  
population. Calculations below assume that 100% of the randomized participants will be 
evaluabl e for safet y analyses. There is an 80% chance of observing at least 1SAE among 
300participants in the V114 group if the underl ying incidence of a SAE is 0.54% (1 of every  
186participants receiving the vaccine). There is a 50% chance of observing at least 1SAE
among 300partici pants in the V114 group if the underly ing incidence of a SAE is 0.23% 
(1of every  433participants receiving the vaccine). If no SAE s are observed among the 
300participants in the V114 group, this stud y will provide 97.5% confidence that the 
underly ing pe rcentage of participants with a SAE is <1.22% (1in every  81participants) in 
the V114 group.
Table 7summarizes the percentage point differences between the 2 vaccination groups that 
could be detected with 80% probability  for a variety  of hypothetical underly ing incidences of 
an adverse event. These calculations assume 300 participants in each group and are based on 
a 2-sided 5% alpha level. The calculations are based on an as ymptotic method proposed by  
[CONTACT_63541] (1990) [Farrington, C. P. 1990] ; no multiplicity  adjustments were 
made. 
  04Y2RW 
  05KFF2
PRODUCT: V114 69
PROTOCOL/AMENDMENT N O.: 016 -01 
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
Table 7 Differences in Incidence of AE Rates between the 2 Vaccination Groups That Can 
be Detected With an ~80% Probability  (Assuming 2-sided 5% alpha level with 300 
Participants in each Group)
Incidence of Adverse Event Risk Difference
Prevnar 13™ (%) V114 (%) Percentage Points
0.1 2.9 2.8
2.0 6.6 4.6
5.0 11.2 6.2
10.0 17.9 7.9
15.0 24.0 9.0
20.0 29.9 9.9
30.0 40.9 10.9
Incidences presented here are hypothetical and do not represent actual adverse experiences in either group.
Based on an asymptotic method [Farrington, C. P. 1990]
9.[ADDRESS_68572] is consistent across various age sub groups (ie, 
50 to 64, 65 to 74 y ears, and ≥75 years) , the estimate of the between -group intervention
effect (with a nominal 95% CI) will be summarized for the primary  immunogenicity  
endpoint for each age subgroup. The 95% CI will only  be calculated if there are more than 
10participants in each vaccination group for each age subgroup. In addition, a summary  of 
AEs and a summary  of solicited AEs will be provided for each age subgroup (point estimates 
only).
9.11 Compliance (Medication Adherence)
Given that participants will receive just a single dose of V11 4 or Prevnar 13™ and a single 
dose of PNEUMOVAX™23, compliance will not be calculated. Ho wever, the number and 
proportion of randomized participants receiving each vaccination will be summarized
(Section 9.12).
9.12 Extent of Exposure
The extent of exposure will be summarized by  [CONTACT_63542] V11 4or Prevnar 13™ and the number and proportion of 
randomized participants administered PNEUMOVAX™[ADDRESS_68573]: V114 70
PROTOCOL/AMENDMENT N O.: 016 -01 
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
10 SUPPORTING DOCUMENTA TION AND OPERATIONAL
CONSIDERATIONS
10.1 Appendix 1: Regu latory, Ethical, and Study Oversight Considerations
10.1.[ADDRESS_68574] for Clinical Trials
[COMPANY_006] Sharp and Dohme Corp., a subsidiary of [COMPANY_006] & Co., Inc. (MSD)
Code of Conduct for Interventional Clinical Trials
I. Introduction
A.Purpose
MSD, through its subsidiaries, conducts clinical trials worldwide to evaluate the safety and effectiveness of our 
products. As such, we are committed to designing, implementing, conducting, analyzing and reporting these trials 
in compliance with the highest ethical and sci entific standards. Protection of participant s inclinical trials is the 
overriding concern in the design of clinical trials . In all cases, M SD clinical trials will be conducted in compliance 
with local and/or national regulations (eg, International Council for Harmonisation Good Clinical Practice [ICH -
GCP]) and in accordance with the ethical principles that have their origin in the Declaration of Helsinki.
B.Scope
Highest ethical and scientific standards shall be endorsed for all clinical interventional in vestigations sponsored by 
[CONTACT_19481] (parties) employed for their execution (eg, contract research organizations, 
collaborative research efforts). This Code is not intended to apply to trials that are observational in nature, or 
which are retrospective. Further, this Code does not apply to investigator -initiated trials , which are not under the 
full control of M SD.
II.Scientific Issues
A.Trial Conduct
1.Trial Design
Except for pi[INVESTIGATOR_19354], clinical trial protocols will be hypothesis -driven to assess safety, 
efficacy, and/or pharmacokinetic or pharmacodynamic indices of M SD or comparator products. 
Alternatively, M SDmay conduct outcomes research trials, trials to assess or validate various endpoint 
measures, or trials to de termine patient preferences, etc.
The design (ie, participant population, duration, statistical power) must be adequate to address the specific
purpose of the trial. P articipants must meet protocol entry criteria to be enrolled in the trial. 
2.Site Selec tion
MSD selects investigative sites based on medical expert[INVESTIGATOR_18700], access to appropriate participants, adequacy of 
facilities and staff, previous performance in clinical trials, as well as budgetary considerations. Prior to trial 
initiation, sites are evalua ted by M SD personnel to assess the ability to successfully conduct the trial.
3.Site Monitoring/Scientific Integrity
Investigative t rial sites are monitored to assess compliance with the trial protocol and general principles of 
Good Clinical Practice (GCP ). MSD reviews clinical data for accuracy, completeness, and consistency. Data 
are verified versus source documentation according to standard operating procedures. Per M SD policies and 
procedures, if fraud, scientific/research misc onduct, or serious GCP -noncompliance is suspected, the issues  
  04Y2RW 
  05KFF2
PRODUCT: V114 71
PROTOCOL/AMENDMENT N O.: 016 -01 
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
areinvestigated. When necessary, the clinical site will be closed, the responsible regulatory authorities and 
ethics review committees notified.
B. Publication and Authorship
Regardless of trial outcome, MSD comm its to publish primary and secondary results of its registered trials of 
marketed products in which treatment is assigned, according to the prespecified plans for data analysis. To the 
extent scientifically appropriate, M SDseeks to publish the results of other analyses it conducts that are important 
to patients, physicians, and payers. Some early phase or pi[INVESTIGATOR_26346] -generating rather 
than hypothesis testing , in such cases, publication of results may not be appropriate since the trial may be 
underpowered and the analyses complicated by [CONTACT_19482].
MSD’s policy on authorship is consistent with the re commendations published by [CONTACT_26399] (ICMJE). In summary , authorship should reflect significant contribution to the design and 
conduct of the trial, performance or interpretation of the analysis, and/or writing of the manuscript. All named 
authors must be able to defend the trial results and conclusions. M SD funding of a trial will be acknowledged in 
publications.
III.Participant Protection
A. Ethics Committee Review (Institutiona Review Board [ IRB]/Independent Ethics Committee [ IEC])
All clinical trials will be reviewed and approved by [CONTACT_2717]/IEC before being initiated at each site. Significant 
changes or revisions to the protocol will be approved by [CONTACT_63543], except 
changes required urgently to prot ect participant safety that may be enacted in anticipation of ethics committee 
approval. For each site, the ethics committee and M SDwill approve the par ticipant informed consent form.
B. Safety
The guiding principle in decision -making in clinical trials i s that participant welfare is of primary importance. 
Potential participants will be informed of the risks and benefits of, as well as alternatives to, trial participation. At 
a minimum, trial designs will take into account the local stand ard of care.
All p articipation in M SD clinical trials is voluntary. Participants enter the trial only after informed consent is 
obtained. Participants may withdraw from a n MSD trial at any time, without any influence on their access to, or 
receipt of, medical care that may otherwise be available to them.
C. Confidentiality
MSD is committed to safeguarding participant confidentiality, to the greatest extent possible. Unless required by 
[CONTACT_2371], only the investigator, Sponsor (or representative), ethics committee, and/or regulator y authorities will have 
access to confidential medical records t hat might identify the participant by [CONTACT_2300].
D. Genomic Research
Genomic r esearch will only be conducted in accordance with a protocol and informed consent authorized by [CONTACT_63544] c ommittee.
IV. Financial Considerations
A. Paym ents to Investigators
Clinical trials are time -and labor -intensive. It is M SD’s policy to compensate investigators (or the sponsoring 
institution) in a fair manner for the work performed in support of M SD trials. M SD does not pay incentives to 
enroll participants in its trials. However, when enrollment is particularly challenging, additional payments may be 
made to compensate for the time spent in extra recruiting efforts. 
  04Y2RW 
  05KFF2
PRODUCT: V114 72
PROTOCOL/AMENDMENT N O.: 016 -01 
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
MSD does not pay for participant referrals. Ho wever, M SDmay compensate referring physicians for time spent 
on chart review to identify potentially eligible participants.
B.Clinical Research Funding
Informed consent forms will disclose that the trial is sponsored by M SDand that the investigator or s ponsoring 
institution is being paid or provided a grant for performing the trial. However, the local ethics committee may 
wish to alter the wording of the disclosure statement to be consistent with financial practices at that institution. As 
noted above, all publications resulting from M SD trials will indicate M SD as a source of funding.
C. Funding for Travel and Other Requests
Funding of travel by [CONTACT_19488] (eg, to scientific meetings, investigator meetings, etc.) will be 
consistent w ith local guidelines and practices .
V. Investigator Commit ment
Investigators will be expected to review M SD’s Code of Conduct as an appendix to the trial protocol, and in signing the 
protocol, agree to support these ethical and scientific standards.
10.1.2 Financ ial Disclosure
Financial Disclosure requirements are outlined in the US Food and Drug Administration 
Regulations, Financial Disclosure b y Clinical I nvestigators (21 CFR Part 54). I t is the 
Sponsor's responsibility  to determine, based on these regulations, whether a request for 
Financial Disclosure information is required. It is the investigator's/subinvestigator's 
responsibility  to comply  with any  such request.
The investigator/subinvestigator(s) agree, if requested by  [CONTACT_19489] 21 
CFR Part 54, to provide his/her financial interests in and/or arrangements with the Sponsor to 
allow for the submission of complete and accurate certification and disclosure statements. 
The investigator/subinvestigator(s) further agree to provide this informat ion on a 
Certification/Disclosure Form, commonly  known as a financial disclosure form, provided by  
[CONTACT_1034]. The investigator/subinvestigator(s) also consent to the transmission of this 
information to the Sponsor in the [LOCATION_002] for these purposes. This may  involve the 
transmission of information to countries that do not have laws protecting personal data.
10.1.3 Data Protection
Participants will be assigned a unique identifier by [CONTACT_1034]. An y participant records or 
datasets that are transferred to th e Sponsor will contain the identifier only; participant names 
or an y information that would make the participant identifiable will not be transferred.
The participant must be informed that his/her personal study -related data will be used by  [CONTACT_19490]. The level of disclosure must also be 
explained to the participant. 
The participant must be informed that his/her medical records may  be examined by  [CONTACT_63545] l appointed by  [CONTACT_941] S ponsor, by  
[CONTACT_6667]/IEC members, and b y inspectors from regulatory authorities. 
  04Y2RW 
  05KFF2
PRODUCT: V114 73
PROTOCOL/AMENDMENT N O.: 016 -01 
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
[IP_ADDRESS] Confidentiality of Data
By [CONTACT_12570], the investigator affirms to the Sponsor that information furnished to 
the investigator by [CONTACT_63546], and such information will 
be divulged to the IRB, IEC,or similar or expert committee; affiliated institution and 
employ ees, only  under an appropriate understanding of confidentialit y with such board or 
committee, affiliated institution and employ ees. Data generated b y this study will be 
considered confidenti al by  [CONTACT_093], except to the extent that it is included in a 
publication as provided in the Publications section of this protocol.
[IP_ADDRESS] Confidentiality of Participant Records
By [CONTACT_12570], the investigator agrees that the Sponsor (or Sponso r representative), 
IRB/IEC, or regulatory  authority  representatives may  consult and/or cop y study  documents to 
verify  worksheet/ CRF report form data. By  [CONTACT_17317], the participant agrees 
to this process. If stud y documents will be photocopie d during the process of verify ing 
worksheet/ CRF information, the participant will be identified b y unique code only; full 
names/initials will be masked prior to transmission to the Sponsor.
By [CONTACT_12570], the investigator agrees to treat all par ticipant data used and 
disclosed in connection with this study  in accordance with all applicable privacy  laws, rules 
and regulations.
[IP_ADDRESS] Confidentiality of IRB/IEC Information
The Sponsor is required to record the name [CONTACT_19525]/IEC that reviews and 
approves this study . The Sponsor is also required to document that each IRB/IEC meets 
regulatory  and ICH GCP requirements b y requesting and maintaining records of the names 
and qualifications of the IRB/IEC members and to make these records available for 
regulatory  agency  review upon request b y those agencies.
10.1.4 Committees Structure
[IP_ADDRESS] Scientific Advisory Committee
This study  was developed in collaboration with a Scientific Advisory  Committee (SAC). The 
SAC is comprise d of both Sponsor and non -Sponsor scien tific experts who provide input 
with respect to study  design, interpretation of study  results, and subsequent peer -reviewed 
scientific publications.
[IP_ADDRESS] Executive Oversight Committee
The Executive Oversight Committee (EOC) is comprise d  of members of Sponsor S enior 
Management. The EOC will receive and decide upon any  recommendations made by  [CONTACT_63547] . 
  04Y2RW 
  05KFF2
PRODUCT: V114 74
PROTOCOL/AMENDMENT N O.: 016 -01 
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
[IP_ADDRESS] External D ata Monitoring Committee
To supplement the routine study monitoring outlined in this protocol, an external DMC will 
monitor t he interim data from this study. The voting members of the committee are external 
to the Sponsor. The members of the DMC must not be involved with the study in an y other 
way (eg, they  cannot be study  investigators) and must have no competing interests that could 
affect their roles with respect to the study .
The DMC will make recommendations to the EOC regarding steps to ensure both participant 
safet y and the continued ethical integrity of the study. Also, the DMC will review interim 
study  results, consider the overall risk and benefit to study  participants (Section 9.7) and 
recommend to the EOC whether the stud y should continue in accordance with the protocol.
Specific details regarding composition, responsibilities, and governance, including the roles 
and responsibilities of the various members and the Sponsor protocol team ; meeting 
facilitation; the study  governance structure; and requirements for and proper documentation 
of DMC reports, minutes, and recommendations will be described in the DMC charter tha t is 
reviewed and approved by [CONTACT_63548].
10.1.[ADDRESS_68575] (FDAAA) o f 2007 
and the European Medicines Agency (EMA) clinical trial Directive 2001/20/EC, the Sponsor 
of the study  is solel y responsible for determining whether the stud yand its results are subject
to the requirements for submission to http://www.clinicaltrials .gov, 
www.clinicaltrialsregister.eu or other local registries. MSD, as Sponsor of this study , will 
review this protocol and submit the information necessary  to fulfill these requirements. MSD 
entries are not limited to FDAAA or the EMA clinical trial direc tive mandated trials. 
Information posted will allow participants to identify  potentiall y appropriate studies for their 
disease conditions and pursue participation b y calling a central contact [CONTACT_63549] d study  site contact [CONTACT_3031]. 
  04Y2RW 
  05KFF2
PRODUCT: V114 75
PROTOCOL/AMENDMENT N O.: [ADDRESS_68576] the study  in an efficient and 
diligent manner and in conformance with this protocol; generall y accepted standards of G CP
(eg, International Conference on Harmonization of Technical Requirements for Registration 
of Pharmaceuticals for Human Use GCP: Consolidated Guideline and other generally  
accepted standards of good clinical practice); and all applicable federal, state and local laws, 
rules and regulations relating to the conduct of the clinical study. The Code of Conduct, a 
collection of goals and considerations that govern the ethical and scientific conduct of 
clinical investigations s ponsored by  [CONTACT_19487], is provided i n this appendix under the Code of 
Conduct for Clinical Studies.
The investigator agrees not to seek reimbursement from participants, their insurance 
providers, or from government programs for procedures included as part of the study  
reimbursed to the investigator b y the Sponsor.
The investigator will promptly  inform the Sponsor of an y regulatory authority inspection 
conducted for this study .
The investigator agrees to provide the Sponsor with relevant information from inspection 
observations/findings to allow the Sponsor to assist in responding to an y citations resulting 
from regulatory  authority inspection and will provide the Sponsor with a copy  of the 
proposed response for consultation before submission to the regulatory  authority . 
Persons debarred from conducting or working on clinical studies by  [CONTACT_63550]’s stu dies. The investigator 
will immediately  disclose in writing to the Sponsor if any  person who is involved in 
conducting the study  is debarred or if any  proceeding for debarment is pending or, to the best 
of the investigator’s knowledge, threatened.
10.1.8 Data Qua lity Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the Sponsor or designee electronically (eg, laboratory data). The investigator 
or qualified designee is responsible for verify ing that data entries are accurate and correct b y 
physicall y or electronically signing the CRF.
Detailed information regarding Data Management procedures for this protocol will be 
provided separatel y.
The investigator must maintain accurate documentation (sour ce data) that supports the 
information entered in the CRF. 
  04Y2RW 
  05KFF2
PRODUCT: V114 76
PROTOCOL/AMENDMENT N O.: [ADDRESS_68577] permit study -related monitoring, audits, IRB/IEC review, and 
regulatory  agency  inspections and provide direct access to source data documents.
Study  documentation will be prom ptly and fully  disclosed to the Sponsor by [CONTACT_63551], 
copy ing, review, and audit at reasonable times b y representatives of the Sponsor or an y 
regulatory  auth orities. The investigator agrees to promptly  take an y reasonable steps that are 
requested b y the Sponsor or any regulatory  authorit ies as a result of an audit or inspection to 
cure deficiencies in the stud y documentation and worksheets/CRFs .
The Sponsor or designee is responsible for the data management of this study  including 
quality  checking of the data.
Study  monitors will perform ongoing source data review and verification to confirm that data 
entered into the CRF b y authorized site personnel are accura te, complete, and verifiable from 
source documents; that the safet y and rights of participants are being protected; and that the 
study  is being conducted in accordance with the currentl y approved protocol and an y other 
study  agreements, ICH GCP, and all ap plicable regulatory  requirements.
Records and documents, including signed ICF, pertaining to the conduct of this study  must 
be retained b y the investigator for 15 ye ars after study  completion unless local regulations or 
institutional policies require a lon ger retention period. No records may  be destroy ed during 
the retention period without the written approval of the Sponsor. No records may be 
transferred to another location or part y without written notification to the Sponsor.
10.1.9 Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrit y of the data collected. Source documents are filed at the investigator’s site.
Data reported on the CRF or entered in the eCRF that are transcribed from source do cuments 
must be consistent with the source documents or the discrepancies must be explained. The 
investigator may  need to request previous medical records or transfer records, depending on 
the study . Also, current medical records must be available.
10.1.10 Study a nd Site Closure
The Sponsor or its designee may  stop the study  or study  site participation in the study  for 
medical, safety , regulatory , administrative, or other reasons consistent with applicable laws, 
regulations, and GCP.
In the event the Sponsor premat urely terminates a particular stud y site, the Sponsor will 
promptly  notify  that study  site’s IRB/IEC. 
  04Y2RW 
  05KFF2
PRODUCT: V114 77
PROTOCOL/AMENDMENT N O.: 016 -01 
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
10.2 Appendix 2: Clinical Laboratory Tests
The tests detailed in Table 8will be performed according to local requirements.
Protocol -specific requirements for inclusion or exclusion of participants are detailed 
in Section 5 of the protocol.
Additional tests may  be performed at an y time during the study as determined 
necessary  by [CONTACT_63552] b y local regulations.
Table 8 Protocol- Required Safet y Laboratory  Assessments
Laboratory  
AssessmentsParameters
Other 
Screening 
TestsSerum or urine β -hCG pregnancy  test (as needed for WOCBP)
β-hCG=β human chorionic gonadotropin; WOCBP=w oman/women of childbearing potential 
  04Y2RW 
  05KFF2
PRODUCT: V114 78
PROTOCOL/AMENDMENT N O.: 016 -01 
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
10.3.1 Definition of AE
AE definition
•An AE is an y untoward medical occurrence in a clinical study participant, temporally 
associated with the use of study  intervention, whether or not considered related to the 
study  intervention.
•NOTE: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of a study  intervention.
•NOTE: For purposes of AE definition, study  intervention (also referred to as Sponsor’s 
product) includes an y pharmaceutical product, biological product, vaccine, device, 
diagnostic agent, or protocol specified procedure whether investigational (including 
placebo or active comparator product) or marketed, manufactured b y, licensed by, 
provided b y, or distributed by [CONTACT_63553].
Events meeting the AE definition
•Any abnormal laboratory test results (hema tology , clinical chemistry, or urinaly sis) or 
other safet y assessments (eg, electrocardiogram , radiological scans, vital signs 
measurements), including those that worsen from baseline, or are considered clinically 
significant in the medical and scientific judgment of the investigator.
•Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency  and/or intensity  of the condition.
•New conditions detected or diagnosed after stud y intervention administration even 
though it may  have been present before the start of the study .
•Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
•Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
intervention or a concomitant med ication.
•For all reports of overdose (whether accidental or intentional) with an associated AE, the 
AE term should reflect the clinical s ymptoms or abnormal test result. An overdose 
without any  associated clinical sy mptoms or abnormal laboratory  results is reported using 
the terminology  “accidental or intentional overdose without adverse effect.”
•Any new cancer or progression of existing cancer. 
  04Y2RW 
  05KFF2
PRODUCT: V114 79
PROTOCOL/AMENDMENT N O.: 016 -01 
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
Events NOT meeting the AE d efinition
•Medical or surgical procedure (eg, endoscop y, appendectom y): the condition t hat leads to 
the procedure is the AE.
•Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
•Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present or 
detected a t the start of the study  that do not worsen.
•Surgery  planned prior to informed consent to treat a pre -existing condition that has not 
worsened.
•Refe r to Section 8.4.[ADDRESS_68578] medical occurrence that, at any dose:
a.Results in death
b.Is life -threatening
•The term “ life-threatening ”in the definition of “serious ”refers to an event in which 
the participant was at risk of death at the time of the event. It does not refer to an 
event, which h ypothetically  might have caused death, if it were more severe.
c.Requires inpatient hospi[INVESTIGATOR_1081]
•Hospi[INVESTIGATOR_19357], regardless of length of stay, even 
if the hospi[INVESTIGATOR_2138] a precautionary  measure for continued observation. (Note: 
Hospi[INVESTIGATOR_19358] a pre -existing c ondition that has not 
worsened is not an SAE. A pre -existing condition is a clinical condition that is 
diagnosed prior to the use of an MSD product and is documented in the participant’s 
medical history .
d.Results in persistent or significant disability/inca pacity
•The term disability  means a substantial disruption of a person’s ability  to conduct 
normal life functions.
•This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiti ng, diarrhea, influenza, 
and accidental trauma (eg, sprained ankle) that may interfere with or prevent 
every day life functions but do not constitute a substantial disruption. 
  04Y2RW 
  05KFF2
PRODUCT: V114 80
PROTOCOL/AMENDMENT N O.: 016 -01 
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
e.Is a congenital anomaly/birth defect
•In offspring of participant taking the pro duct regardless of time to diagnosis.
f.Other important medical events
•Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that may 
not be immediately  life-threatening or result in death or hospi[INVESTIGATOR_63474] [ADDRESS_68579] es of such events include invasive or malignant cancers, intensive treatment in 
an emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency 
or drug abuse.
10.3.3 Additional Events Reported
Additional events that require r eporting
In addition to the above criteria, AEs meeting either of the below criteria, although not 
serious per ICH definition, are reportable to the Sponsor.
•Is a cancer
•Is associated with an ove rdose
10.3.4 Recording AE and SAE
AE and SAE r ecording
•When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory , and diagnostics reports) related to 
the event.
•The investigator will record all relevant AE/SAE information on the AE 
CRFs /worksheets at each examination.
•It is not acceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s medical 
records to the Sponsor in lieu of completion of the AE C RF page.
•There may  be instances when copi[INVESTIGATOR_63475] b y 
the Sponsor. I n this case, all participant identifiers, with the exception of the participant 
number, will be blinded on the copi[INVESTIGATOR_63476].
•The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. I n such cases, the diagnosis (not the 
individual signs/sy mptoms) will be documented as the AE/ SAE. 
  04Y2RW 
  05KFF2
PRODUCT: V114 81
PROTOCOL/AMENDMENT N O.: 016 -01 
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
Assessment of Intensity /Toxicity
•An event is defined as “serious ”when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, not when it is rated as severe.
•The investigator will make an assessment of intensity  for each AE and SAE (and other 
reportable safet y event) reported during the stud y and assign it to 1 of the following 
categories:
-Mild: An event that is easily  tolerated b y the participant, causing minimal discomfort 
and not interfering with every day activiti es (for pediatric studies, awareness of 
symptoms, but easily  tolerated).
-Moderate: An event that causes sufficient discomfort to interfere with normal 
every day activities (for pediatric studies definitel y acting like something is wrong).
-Severe: An event t hat prevents normal every day activities. An AE that is assessed as 
severe should not be confused with an SAE. Severe is a category  utilized for rating 
the intensity  of an event; and both AE and SAE can be assessed as severe (for 
pediatric studies, extremel y distressed or unable to do usual activities).
•Injection -site redness /erythema or swelling from the day of vaccination through Day  5 
postvaccination will be evaluated b y maximum size.
•The investigator will make an assessment of toxicity for each AE and SA E (and other 
reportable event) reported during the stud y.  A toxicity  grade will be assigned to 
injection -site AEs, specific sy stemic AEs, other s ystemic AEs, and vital sign 
(temperature) AEs as shown in the following tables. The toxicity  grading scales us ed in 
this study  are adapted from the “FDA Guidance for Industry : Toxicity  Grading Scale for 
Health y Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, 
September 2007.” 
  04Y2RW 
  05KFF2
PRODUCT: V114 82
PROTOCOL/AMENDMENT N O.: 016 -01 
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
Injection -Site AE Toxicity Grading Scale
Injection Site Re action 
to Study 
Vaccine/PlaceboaGrade 1 Grade 2 Grade 3 Grade 4
Injection -site AEs occurring Days 1 through 5 following receipt of study vaccine/placebo
Pain/Tenderness Does not interfere 
with activityRepeated use of non -
narcotic pain reliever 
>24 hours or 
interferes with 
activityAny use of narcotic 
pain reliever or 
prevents daily 
activityERvisit or 
hospi[INVESTIGATOR_2666]/Redness Size measured as
BSize measured as
C or DSize measured as
E→Necrosis or 
exfoliative dermatitis 
or results in ER visit 
or hospi[INVESTIGATOR_63477]/Swelling Size measured as 
BSize measured as
C or DSize measured as
E→Necrosis or ER visit 
or hospi[INVESTIGATOR_63478] -
narcotic pain reliever 
>24 hours or 
interfere s with 
activityAny use of narcotic 
pain reliever or 
prevents daily 
activityER visit or 
hospi[INVESTIGATOR_63479] -site reaction that begins ≥ 6 days after receipt of study vaccine/placebo
Pain/tenderness
Erythema/Redness
Induration/Swelling
OtherDoes not interfere 
with activityRepeated use of non -
narcotic pain reliever 
>24 hours or 
interferes with 
activityAny use of narcotic 
pain reliever or 
prevents daily 
activityER visit or 
hospi[INVESTIGATOR_63480]: AE=adverse event; ER=emergency room; eVRC=electronic vaccine report card; SAE=serious adverse event
a Based upon information provided by [CONTACT_63554]. Erythema/Redness and 
Induration /Swelling are specific injection -site AEs with size designations of letters A through E →, bas ed upon a graphic in 
the eVRC. Size A is not assigned a toxicity grade; however, injection -site AEs that measure size A should be re ported as 
adverse experiences. If the participant has an ER visit or is hospi[INVESTIGATOR_63481] -site AE, that AE is to be assigned a 
toxicity grade of 4, regardless of the size measured.
Specific Systemic AE Toxicity Grading Scale
System ic (General)Mild 
(Grade 1)Moderate 
(Grade 2)Severe 
(Grade 3)Potentially Life 
Threatening
(Grade 4)
Headache No interference with 
activityRepeated use of non -
narcotic pain reliever 
>24hours or some 
interference with 
activitySignificant; any use of 
narcotic pain reliever 
or prevents daily 
activityER visit or 
hospi[INVESTIGATOR_63482]; prevents 
daily activityER visit or 
hospi[INVESTIGATOR_63483]; prevents 
daily activityER visit or 
hospi[INVESTIGATOR_63484]: AE=adverse event; ER= emergency room 
  04Y2RW 
  05KFF2
PRODUCT: V114 83
PROTOCOL/AMENDMENT N O.: 016 -01 
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
Other Systemic AE Toxicity Grading Scale
System ic IllnessaMild 
(Grade 1)Moderate 
(Grade 2)Severe 
(Grade 3)Potentially Life 
Threatening
(Grade 4)b
Illness or clinical AE 
(as defined according 
to applicable 
regulations)No interference with 
activitySome interference with 
activity not requiring 
medical interventionPrevents daily activity 
and required medical 
interventionER visit or 
hospi[INVESTIGATOR_63480]: AE=adverse event; ER=emergency room; eVRC= electronic vaccine report card; SAE= serious adverse event
aBased upon information provided by [CONTACT_63555] -up period. For SAEs reported beyond the primary safety follow -up period, grading will be based upon the 
initial report and/or f ollow -up of the event.
bAEs resulting in death will be assessed as Grade 4
Vital Sign (Temperature) Toxicity Grading Scale
Vital SignsaMild 
(Grade 1)Moderate 
(Grade 2)Severe 
(Grade 3)Potentially Life 
Threatening
(Grade 4)
Fever (°C)b
(°F)b38.0 to 38.4
100.4 to 101.138.5 to 38.9
101.2 to 102.039.0 to 40.0
102.1 to 104.0>40.0
>104.[ADDRESS_68580] for all vital sign requirements
b Oral temperature; no recent hot or cold beverages or smoking
Assessment of c ausality
•Did the Sponsor ’s product cause the AE?
•The determination of the likelihood that the Sponsor ’s product caused the AE will be 
provided b y an investigator who is a qualified physician. The investigator’s signed/dated 
initials on the source document or worksheet that supports the causalit y noted on the AE 
form, ensures that a medically  qualified assessment of causalit y was done. This initia lled 
document must be retained for the required regulatory time frame. The criteria below are 
intended as reference guidelines to assist the investigator in assessing the likelihood of a 
relationship between the test product and the AE based upon the available information.
•The following components are to be used to assess the relationship between the 
Sponsor ’s product and the AE; the greater the correlation with the components and 
their respective elements (in number and/or intensity ), the more likel y the Sponsor ’s 
product caused the AE:
-Exposure: Is there evidence that the participant was actuall y exposed to the 
Sponsor ’s product such as: reliable history , acceptable compliance assessment (diary , 
etc.), seroconversion or identification of vaccine virus in bodily  specimen?
-Time Course: Did the AE follow in a reasonable temporal sequence from 
administration of the Sponsor ’s product? Is the time of onset of the AE compatible 
with a vaccine -induced effect? 
  04Y2RW 
  05KFF2
PRODUCT: V114 84
PROTOCOL/AMENDMENT N O.: 016 -01 
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
-Likely Cause: Is the AE not reasonabl y explained by  [CONTACT_63556], other drug(s)/vaccine(s), or other host or environmental factors ?
-Rechallenge: Was th e participant re -exposed to the Sponsor ’s product in the study ?
-If yes, did the AE recur or worsen?
-If yes, this is a positive rechallenge.
-If no, this is a negative rechallenge.
(Note: This criterion is not applicable if: (1) the initial AE resulted in de ath or permanent 
disability , or (2) the study  is a single -dose vaccine study ); or (3) Sponsor ’s product(s) is/are 
used only  1 time.)
NOTE: IF A RECHALLENGE IS PL ANNED FOR AN AE THAT WAS SERI OUS AND 
MAY HAVE BEEN CAUSED BY [CONTACT_26370] ’S PRODUCT, OR I F RE -EXPOSURE 
TO THE SPONSOR ’S PRODUCT POSES ADDITIONAL POTENTIAL SI GNIFICANT 
RISK TO THE PARTI CIPANT THEN THE RECHALLENGE MUST BE APPROVED I N 
ADVANCE BY [CONTACT_63557], AND IF REQUI RED, THE 
IRB/IEC .
-Consistency with study intervention profile: Is the clinical/pathological 
presentation of the AE consistent with previous knowledge regarding the Sponsor ’s 
product or drug class pharmacology  or toxicology?
-The assessment of relationship will be reported on the CRFs /worksheets by [CONTACT_26368] a qualified phy sician according to his/her best clinical judgment, 
including consideration of the above elements.
-Use the following scale of criteria as guidance (not all criteria must be present to be 
indicative of a Sponsor ’s product relationship).
-Yes, there is a reasonable possibility  of Sponsor ’s product relationship:
-There is evidence of exposure to the Sponsor ’s product. The temporal sequence of the 
AE onset relative to the administration of the Sponsor ’s product is reasonable. The 
AE is more likely  explained by [CONTACT_1034] ’s product than by  [CONTACT_5748].
-No, there is not a reasonable possibility  of Sponsor ’s product relationship:
-Participant did not receive the Sponsor ’s product OR temporal sequence of the AE 
onset relative to administration of the Sponsor ’s product is not reasonable OR the AE 
is more likely  explained by  [CONTACT_26372]’s product. (Also entered 
for a participant with overdose without an associated AE.)
•For each AE/SAE, the investigator must document in the medical note s that he/she has 
reviewed the AE/SAE and has provided an assessment of causalit y.
•There may  be situations in which an SAE has occurred and the investigator has minimal 
information to include in the initial report to the Sponsor. However, it is very import ant 
that the investigator always make an assessment of causalit y for every event before the 
initial transmission of the SAE data to the Sponsor. 
  04Y2RW 
  05KFF2
PRODUCT: V114 85
PROTOCOL/AMENDMENT N O.: 016 -01 
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
•The investigator may change his/her opi[INVESTIGATOR_19954] -up 
information and send an SAE foll ow-up report with the updated causality  assessment.
•The causality  assessment is 1 of the criteria used when determining regulatory  reporting 
requirements.
Follow -up of AE and SAE
•The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested b y Sponsor to 
elucidate the nature and/or causalit y of the AE or SAE as fully as possible. This may 
include additional laboratory  tests or investigations, histopathological examinations, or 
consultation with other health care professionals.
•New or updated information will be recorded in the CRF.
•The investigator will submit any  updated SAE data to the Sponsor within 24 hours of 
receipt of the information.
10.3.5 Reporting of AE, SAE, and Other Reportable Safety Events to the Sponsor
AE, SAE, and other reportable safety event reporting to Sponsor via electronic data 
collection tool
•The primary  mechanism for reporting to the Sponsor will be the EDC tool.
•Electronic reporting procedures can be found in the EDC data entry guidelines (or 
equivalent).
•If the electronic s ystem is unavailable for more than 24 hours, then the site will use 
the paper AE Reporting form.
•Reference Section 8.4.1  for reporting time requirements.
•The site will enter the SAE data into the electronic sy stem as soon as it becomes 
available.
•After the stud y is completed at a given site, the EDC tool will be taken off -line to prevent 
the entry  of new data or changes to existing data.
•If a site receives a report of a new SAE from a study  participant or receives updated data 
on a previousl y reported SAE after the EDC tool has been taken off -line, then the site can 
report this information on a paper SAE form or by [CONTACT_756] (see next section).
•Contacts for SAE repo rting can be found in the Investigator Stud y File Binder (or 
equivalent). 
  04Y2RW 
  05KFF2
PRODUCT: V114 86
PROTOCOL/AMENDMENT N O.: 016 -01 
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
SAE reporting to the Sponsor via paper CRF
•If the EDC tool is not operational, facsimile transmission or secure e -mail of the SAE 
paper CRF is the preferred method to transmit this information to the Sponsor.
•In rare circumstances and in the absence of facsimile equipment, notification by  
[CONTACT_9337] a cop y of the SAE data collection tool sent by [CONTACT_19515].
•Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time frames.
•Contacts and instructions for SAE reporting and paper reporting procedures can be found 
in the Investigator Study  File Binder (or equivalent). 
  04Y2RW 
  05KFF2
PRODUCT: V114 87
PROTOCOL/AMENDMENT N O.: 016 -01 
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
10.4 Appendix 4: Medical Device Incidents: Definition and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
Not applicable 
  04Y2RW 
  05KFF2
PRODUCT: V114 88
PROTOCOL/AMENDMENT N O.: 016 -01 
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
10.5 Appendix 5: Contraceptive Guidance and Pregnancy Testing
10.5.1 Definitions
Wome n of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanentl y sterile.
Women in the following categories are not considered WOCBP:
•Premenarchal
•Premenopausal female with 1 of the following:
- Documented hysterectomy
-Documented bilateral salpi[INVESTIGATOR_1656]
-Documented bilateral oophorectom y
Note: Documentation can come from the site personnel’s review of the participant’s medical 
records, medical examination, or medical history  interview.
•Postmenopausal female
- A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause .
•A high follicle -stimulating hormone (FSH) level in the postmenopausal range may  be 
used to confirm a postmenopausal state in women not using hormonal contrace ption or 
hormone replacement therap y (HRT). However, in the absence of [ADDRESS_68581]: V114 89
PROTOCOL/AMENDMENT N O.: 016 -01 
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
Table 9 Contraceptive Methods
Acceptable Contraceptive Methods
Failure rate of >1% per year when used consistently and correctly.
●Male or female condom with or without spermicide
●Cervical cap, diaphragm or sponge with spermicide
Highly Effective Contraceptive Methods That Are User Dependenta
Failure rate of <1% per year when used consistently and correctly.
●Com bined (estrogen -and progestogen -containing) hormonal contraceptionb
○Oral
○Intravaginal
○Transdermal
○Injectable
●Prog estogen only hormonal contraceptionb
○Oral
○Injectable
Highly Effective Methods That Have Low User Dependency
Failure rate of <1% per year when used consistently and correctly.
●Progestogen -only contraceptive implantb,c 
●Intrauterine hormone -releasing system (IUS)b
●Intrauterine device (IUD)
●Bilateral tubal occlusion
●Vasectomized partner
A vasectomized partner is a highly effective contraception method provided that the partner is the sole 
male sexual partner of the WOCBP and the absence of sperm has been confirmed. If not, an additional 
highly effective method of contraception should be used.
●Sexual abstinence
Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual 
intercourse during the entire period of risk associated with the study intervention. The reliability of sexual 
abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual 
lifestyle of the participant.
Notes:
Use should be con sistent with local regulations regarding the use of contraceptive methods for participants 
of clinical studies.
aTypi[INVESTIGATOR_63485] -use failure rates (ie, when used consistently and 
correctly).
bIf locally required, in accordance with Clinical Trial Facilitation Group guidelines, acceptable hormonal 
contraceptives are limited to those which inhibit ovulation. 
  04Y2RW 
  05KFF2
PRODUCT: V114 90
PROTOCOL/AMENDMENT N O.: [ADDRESS_68582]: V114 91
PROTOCOL/AMENDMENT N O.: 016 -01 
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
10.6 Appendix 6: Collection and Management of Specimens for Future Biomedical 
Research
1. Definitions
Biomarker: A biological molecu le found in blood, other body fluids, or tissues that is a 
sign of a normal or abnormal process or of a condition or disease. A biomarker may be 
used to see how well the body  responds to a treatment for a disease or condition . 
Pharmacogenomics: The invest igation of variations of DNA and RNA characteristics as 
related to drug/vaccine response.2
Pharmacogenetics: A subset of pharmacogenomics, pharmacogenetics is the influence of 
variations in DNA sequence on drug/vaccine response.2
DNA: Deox yribonucleic acid .
RNA: Ribonucleic acid.
2. Scope of Future Biomedical Research
The specimens consented and/or collected in this study  as outlined in Section 8. 8will be 
used in various experiments to understand:
•The biology  of how drugs/vaccines work
•Biomarkers responsible for how a drug/vaccine enters and is removed b y the body
•Other pathway s drugs/vaccines may  interact with
•The biology  of disease
The specimen(s) may  be used for future assay  development and/or drug/vaccine 
development.
It is now well recognized that informa tion obtained from study ing and testing clinical 
specimens offers unique opportunities to enhance our understanding of how individuals 
respond to drugs/vaccines, enhance our understanding of human disease and ultimately  
improve public health through develo pment of novel treatments targeted to populations 
with the greatest need. All specimens will be used by [CONTACT_63558].
3. Summary of Procedures for Future Biomedical Research .
1.Participants for Enrollment
All participants enrolled in the clinical study  will be considered for enrollment in the 
future biomedical research substudy 
  04Y2RW 
  05KFF2
PRODUCT: V114 92
PROTOCOL/AMENDMENT N O.: 016 -01 
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
2.Informed Consent
Informed consent for specimens (ie, DNA, RNA, protein, etc.) will be obtained 
during screening for protocol enrollment from all participants or legal guardians, at a 
study  visit by  [CONTACT_63559] d esignate. Informed consent for future 
biomedical r esearch should be presented to the participants on the visit designated in 
the SoA. If delay ed, present consent at next p ossible Participant Visit. Consent forms 
signed b y the participant will be kept at the clinical study site under secure storage for 
regulatory  reasons.
A template of each stud y site’s approved informed consent will be stored in the 
Sponsor’s clinical docum ent repository .
3.eCRF Documentation for Future Biomedical Research Specimens
Documentat ion of participant consent for future biomedical research will be captured 
in the eCRFs . Any specimens for which such an informed consent cannot be verified 
will be destroy ed.
4.Future Biomedical Research Specimen(s)
Collection of specimens for future biomedical r esearch will be performed as outlined 
in the SoA. I n general, if additional blood specimens are being collected for future 
biomedical r esearch, these will usua lly be obtained at a time when the participant is 
having blood drawn for other study  purposes.
4. Confidential Participant Information for Future Biomedical Research
In order to optimize the resea rch that can be conducted with future biomedical r esearch 
speci mens, it is critical to link participant' clinical information with future test results. I n 
fact little or no research can be conducted without connecting the clinical study data to 
the specimen. The clinical data allow specific analyses to be conducted. K nowing 
participant characteristics like gender, age, medical history and treatment outcomes are 
critical to understanding clinical context of anal ytical results.
To maintain privacy  of information collect ed from specimens obtained for future 
biomedical r esearch, the Sponsor has developed secure policies and procedures. All 
specimens will be single -coded per ICH E15 guidelines as described below.
At the clinical study  site, unique codes will be placed on the future biomedical r esearch 
specimens. This code is a random number which does not contain an y personally 
identify ing information embedded within it. The link (or key ) between participant 
identifiers and this unique code will be held at the study  site. No personal identifiers will 
appear on the specimen tu be.
5. Biorepository Specimen Usage
Specimens obtained for the Sponsor will be used for anal yses using good scientific 
practices. Anal yses utilizing the future biomedical r esearch specimens may  be performed 
by [CONTACT_1034], or an additional third party  (eg, a university  investigator) designated by 
[CONTACT_1034]. The investigator conducting the anal ysis will follow the Sponsor’s privacy 
and confidentialit y requirements. An y contracted third part y anal yses will conform to the  
  04Y2RW 
  05KFF2
PRODUCT: V114 93
PROTOCOL/AMENDMENT N O.: [ADDRESS_68583] the Sponsor 
using the designated mailbox ([EMAIL_1250]). 
Subsequently , the participant's specimens will be flagged in the biorepository  and 
restricted to main stud y use only . If specimens were collected from study participants 
specificall y for future biomedical r esearch, these specimens will be removed from the 
biorepository  and destroyed. Documentation will be sent to the investigator confirming 
withdrawal and/or destruction, if applicable. It is the res ponsibility  of the investigator to 
inform the participant of completion of the withdrawal and/or destruction, if applicable. 
Any anal yses in progress at the time of request for withdrawal/destruction or alread y 
performed prior to the request being received by [CONTACT_63560]. No new analy ses would be generated 
after the request is received.
In the event that the medical records for the main study  are no longer available (eg, if the 
investigator is no longer required b y regulatory authorities to retain the main study 
records) or the specimens have been completel y anonymized, there will no longer be a 
link between the participant’s personal information and their specimens. In this situ ation, 
the request for withdrawal of consent and/or destruction cannot be processed.
7. Retention of Specimens
Future biomedical r esearch specimens will be stored in the biorepository  for potential 
analysis for up to [ADDRESS_68584]: V114 94
PROTOCOL/AMENDMENT N O.: [ADDRESS_68585] results are accessible only to the 
authorized Sponsor representatives and the designated study administrator research 
personnel and/or collaborators. Database user authenticati on is highl y secure, and is 
accomplished using network securit y policies and practices based on international 
standards to protect against unauthorized access.
9. Reporting of Future Biomedical Research Data to Participants
No information obtained from exploratory  laboratory  studies will be reported to the 
participant, famil y, or physicians. Principle reasons not to inform or return results to the 
participant include: Lack of relevance to participant health, limitations of predictive 
capability , and conc erns regarding misinterpretation.
If important research findings are discovered, the Sponsor may publish results, present 
results in national meetings, and make results accessible on a public website in order to 
rapi[INVESTIGATOR_63486] a nd participants. Participants will not be 
identified by  [CONTACT_63561].
10. Future Biomedical Research Study Population
Every  effort will be made to recruit all participants diagnosed and treated o n Sponsor 
clinical studies for f uture biomedical r esearch.
11. Risks Versus Benefits of Future Biomedical Research
For future biomedical research, risks to the participant have been minimized and are 
described in the future biomedical r esearch informed consent.
The Sponsor has developed strict security, policies, and procedures to address participant 
data privacy  concerns. Data privacy  risks are largely  limited to rare situations involving 
possible breach of confidentiality . In this high ly unlikely  situation, there is risk that the 
information, like all medical information, may  be misused.
12. Questions
Any questions related to the future biomedical research should be e mailed directly  to 
[EMAIL_1250]. 
  04Y2RW 
  05KFF2
PRODUCT: V114 95
PROTOCOL/AMENDMENT N O.: 016 -01 
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
13. References
1.National Cancer Institute [I nternet]: Available from 
https://www.cancer.gov/publications/dictionaries/cancer -terms?cdrid=[ZIP_CODE]
2.International Conference on Harmonization [Internet] : E15 : Definitions for Genomic 
Biomarkers, Pharmacogenomics, Pharmacogenetics, Genomic Data and Sample 
Coding Categories. Available from 
http://www.ich.org/products/guidelines/efficacy /efficacy -single/article/definitions -
for-genomic -biomarkers -pharmacogenomics -pharmacogenetics -genomic -data-and-
sample -cod.html 
3.Industry  Pharmacogenomi cs Working Group [Internet]: Understanding the I ntent, 
Scope and Public Health Benefits of Exploratory  Biomarker Research: A Guide for 
IRBs/IECs and Investigational Site Staff. Available at http://i -pwg.org/ 
4.Industry  Pharmacogenomics Working Group [Intern et]: Pharmacogenomics 
Informational Brochure for I RBs/IECs and Investigational Site Staff. Available at 
http://i -pwg.org/ 
  04Y2RW 
  05KFF2
PRODUCT: V114 96
PROTOCOL/AMENDMENT N O.: 016 -01 
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
10.7 Appendix 7: Country -specific Requirements
Not applicable 
  04Y2RW 
  05KFF2
PRODUCT: V114 97
PROTOCOL/AMENDMENT N O.: 016 -01 
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
10.8 Appendix 8: Abbreviations
Abbreviation Expanded Term
ACIP Advisory Committee on Immunization Practices
AE adverse e vent
APaT All Participants as Treated
β-hCG beta human chorionic gonadotropin
CAPi[INVESTIGATOR_63487] -Acquired Pneumonia Immunization Trial in Adults
CFR Code of Federal Regulations
CI confidence interval
cLDA constrained longitudinal data a nalysis
CONSORT Consolidated Standards of Reporting Trials
CRF case report form
CSR Clinical Study R eport
DMC Data Monitoring Committee
DNA deoxyribonucleic acid
ECI event of clinical interest
ECL electrochemiluminescence
ECRF electronic case report form
EDC electronic data collection
EMA European Medicines Agency
EOC Executive Oversight Committee
eVRC Electronic Vaccination Report Card
FAS Full Analysis Set
FDAAA Food and Drug Administration Amendments Act
FSH follicle -stimulating hormone
GCP Good Clinical Practice
GMC Geometric Mean C oncentration
GMFR Geometric Mean Fold R ise
GMT Geometric M ean Titer
HIV human immunodeficiency virus
HRT hormone replacement therapy
IB Investigator’s Brochure
ICF Informed Consent F orm
ICH International Council for Harmonisation Good Clinical Practice
IEC Independent Ethics Committee
IgG immunoglobulin G
IMP investigational medicinal product
IPD invasive pneumococcal disease
IRB Institutional Review Board
IRT interactive response technology 
  04Y2RW 
  05KFF2
PRODUCT: V114 98
PROTOCOL/AMENDMENT N O.: 016 -01 
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
Abbreviation Expanded Term
IUD intrauterine device
IUS intrauterine hormone -releasing system
MOPA Multiplexed Opsonophagocytic Assay
MSD [COMPANY_006] Sharp & Dohme Corp.
NIMP non-investigational medicinal product
NSAE non-serious adverse event
OPA opsonophagocytic activity
PCV pneumococcal conjugate vaccine
PnECL pneumococcal electrochemiluminescence
PP Per-Protocol
PT preferred term
RNA ribonucleic acid
SAC Scientific Advisory Committee
SAE serious adverse e vent
SLAB supplemental laboratory test
SoA schedule of activities
SOC system organ class
S[LOCATION_003]R suspected unexpected serious adverse reaction
US United State s
WOCBP woman/women of childbearing potential 
  04Y2RW 
  05KFF2
PRODUCT: V114 99
PROTOCOL/AMENDMENT N O.: 016 -01 
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
11 REFERENCES
[Anttila, M., et al 1999] Anttila M, Voutilainen M, Jäntti V, Eskola J, Käyht y H. 
Contribution of seroty pe-specific IgG concentration, 
IgG subclasses and relative antibody avidity  to 
opsonophagocy tic activity  against Streptococcus 
pneumoniae. Clin Exp Immunol 1999;118(3):402 -7.03QY70
[Bonten, M. J., et al 
2015]Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, 
Patterson S, Gault S, et al. Poly saccharide conjugate 
vaccine against pneumococcal pneumonia in adults. N 
Engl J Med. 2015 Mar 19;372(12):1114 -25.04NFHD
[Burton, Robert L . and 
Nahm , Moon H. 2006]Burton RL, Nahm MH. Development and validation of a 
fourfold multiplexed opsonization assay  (MOPA4) for 
pneumococcal antibodies. Clin Vaccine Immunol 
2006;13(9):1004 -9.03QT2R
[Castiglia P. 2014] Castiglia P. Recommendations for pneumococc al 
immunization outside routine childhood immunization 
programs in Western Europe. Adv Ther. 
2014Oct;31(10):1011 -44.04P7L W
[Centers for Disease 
Control and Prevention 
2008]Centers for Disease Control and Prevention (CDC). 
Invasive pneumococcal disease i n children 5 years after 
conjugate vaccine introduction -eight states,1998 -2005. 
MMWR Morb Mortal Wkly  Rep. 2008 Feb 
15;57(6):144 -8.04KW8S
[Centers for Disease 
Control and Prevention 
2010]Centers for Disease Control and Prevention. Updated 
recommendation s for prevention of invasive 
pneumococcal disease among adults using the 23 -valent 
pneumococcal poly saccharide vaccine (PPSV23). 
MMWR 2010;59(34):1102 -6.03RCFX
[Centers for Disease 
Control and Prevention 
2010]Centers for Disease Control and Prevention. Prevention 
of Pneumococcal Disease Among Infants and Children -
Use of 13 -Valent Pneumococcal Conjugate Vaccine and 
23-Valent Pneumococcal Polysaccharide Vaccine; 
Recommendations of the Advisory  Committee on 
Immunization Practices (ACI P). MMWR 2010;59(RR -
11):1-19.03RSB6
[Collett, D. 1999] Collett D. Statistical inference for binary  data. In: 
Collett D, ed. Modelling Binary  Data. [LOCATION_001]: 
Chapman & Hall, 1999:17 -42.03NVVC
[Drijkoningen, J. J 
2014]Drijkoningen JJ, Rohde GG. Pneumococcal infection in 
adults: burden of disease. Clin Microbiol I nfect. 2014 
May;[ADDRESS_68586] 5:[ADDRESS_68587]: V114 100
PROTOCOL/AMENDMENT N O.: 016 -01 
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
[European Centre for 
Disease Prevention and 
Control 2016]European Centre for Disease Prevention and Control. 
Annual Epi[INVESTIGATOR_63488] 2016 –Invasive 
pneumococcal disea se. [Internet]. Stockholm: ECDC; 
2016. Available from: 
http://ecdc.europa.eu/en/healthtopi[INVESTIGATOR_1102]/pneumococcal_inf
ection/Pages/Annual -epi[INVESTIGATOR_904] -report -2016.aspx.04LP3M
[Farrell, D. J, et al 
2007]Farrell DJ, Klugman KP, Pi[INVESTIGATOR_63489] M. Increased 
antimicro bial resistance among nonvaccine serot ypes of 
Streptococcus pneumoniae in the pediatric population 
after the introduction of [ADDRESS_68588] Dis J. 2007 
Feb;26(2):123 -8.04KWD9
[Farrington, C. P. 1990] Farrington CP, Manning G. Test Statistics and Sample 
Size Formulae for Comparative Binomial Trials with 
Null Hy pothesis of Non -Zero Risk Difference or Non -
Unity  Relative Risk. Stat Med Vol. 9,1447 -1454 (1990)04FS6L
[Guevara, M., et al 
2016]Guevara M, Barricarte A, Torroba L, Herranz M, Gil -
Setas A, Gil F, et al. Direct, indirect and total effects of 
13-valent pneumococcal conjugate vaccination on 
invasive pneumococcal disease in children in Navarra, 
Spain, 2001 to 2014: cohort and case -control study . 
Euro Surveill. 2016;21(14).04KSQ3
[Janssens, J. P. 2004] Janssens JP, Krause KH. Pneumonia in the very  old. 
Lancet Infect Dis. 2004 Feb;4:112 -24.04VTNJ
[Jokinen, J., et al 2015] Jokinen J, Rinta -Kokko H, Siira L , Palmu AA, Virtanen 
MJ, Nohy nek H, et al. Impact of ten -valent 
pneumococcal conjugate vaccination on invasive 
pneumococcal disease in Finnish children a population -
based study . PLoS One. 2015 Mar 17;10(3):e0120290.04KW7F
[Kobay ashi, M., et al 
2015]Kobay ashi M, Bennett NM, Gierke R, Almendares O, 
Moore MR, Whitney  CG, et al. Intervals Between 
PCV13 and PPSV23 Vaccines: Recommendations of the 
Advisory  Committee on Immunization Practices 
(ACI P). MMWR Morb Mortal Wkly  Rep. 2015 Sep 
4;64(34):944 -7.04P7L H
[Lepoutre, A., et al 
2015]Lepoutre A, Varo n E, Georges S, Dorleans F, Janoir C, 
Gutmann L , et al. Impact of the pneumococcal 
conjugate vaccines on invasive pneumococcal disease in 
[LOCATION_009], 2001 -2012. Vaccine. 2015 Jan 3;33(2):[ADDRESS_68589]: V114 101
PROTOCOL/AMENDMENT N O.: 016 -01 
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
[Lexau, C. A., et al 
2005]Lexau CA, Ly nfield R, Danila R, Pi[INVESTIGATOR_63466] T, Facklam 
R, Farley  MM, et al. Changing epi[INVESTIGATOR_63490]. 
JAMA 2005;294(16):2043 -51.03RBPW
[Liang, K -Y and Zeger, 
S. L. 2000]Liang K -Y,Zeger SL. Longitudinal data anal ysis of 
continuous and discrete responses for pre -post designs. 
Sanky ha: The Indian Journal of Statistics 
2000;62(Series B, Part 1):134 -48.00V5V6
[Martinelli, D., et al 
2014]Martinelli D, Pedalino B, Cappelli MG, Caputi G, 
Sallustio A, Fortunato F, et al Towards the 13 -valent 
pneumococcal conjugate universal vaccination: 
effectiveness in the transition era between PCV7 and 
PCV13 in I taly, 2010 -2013. Hum Vaccin I mmunother. 
2014;10(1):33 -9.04KW8B
[Metlay , J. P., et al 
2006]Metlay  JP, Fishman NO, Joffe M, Edelstein PH. Impact 
of pediatric vaccination with pneumococcal conjugate 
vaccine on the risk of bacteremic pneumococcal 
pneumonia in adults. Vaccine 2006;24:468 -75.03RC46
[Miettinen, O. and 
Nurminen, M. 1985]Miettinen O, Nurminen M. Comparative Anal ysis of 
Two Rates. Stat Med 1985;4:213 -26.03QCDT
[Moore, M. R., et al 
2015]Moore MR, L ink-Gelles R, Schaffner W, Ly nfield R, 
Lexau C, Bennett NM, et al. Effect of use of 13 -valent 
pneumococcal conjugate vaccine in children on invasive 
pneumococcal disease in children and adults in the 
[LOCATION_003]: analy sis of multisite, population -based 
surveillance. Lancet Infect Dis. 2015 Feb 3. [Epub 
ahead of print].043MRP
[Palmu, A. A., et al 
2015]Palmu AA, Kilpi [CONTACT_58465], Rinta -Kokko H, N ohynek H, 
Toropainen M, Nuorti JP, et al. Pneumococcal conjugate 
vaccine and clinicall y suspected invasive pneumococcal 
disease. Pediatrics. 2015 Jul;136(1):e22 -7.04KVRL
[Pi[INVESTIGATOR_63466], Tamara, et 
al 2010]Pi[INVESTIGATOR_63466] T, Lexau C, Farley MM, Hadler J, Harriso n 
LH, Bennett NM, et al. Sustained reductions in invasive 
pneumococcal disease in the era of conjugate vaccine. J 
Infect Dis 2010;201(1):[ADDRESS_68590]: V114 102
PROTOCOL/AMENDMENT N O.: 016 -01 
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
[Romero -Steiner, S., et 
al 1997]Romero -Steiner S, L ibutti D, Pais LB, Dy kes J, 
Anderson P, Whitin JC, e t al. Standardization of an 
opsonophagocy tic assay  for the measurement of 
functional antibody  activity  against streptococcus 
pneumoniae using differentiated HL -60 cells. Clin 
Diagn Lab Immunol 1997;4(4):415 -22.03NWQ5
[Ruckinger, S., et al 
2009]Ruckinger S, van der Linden M, Reinert RR, von Kries 
R, Burckhardt F, Siedler A. Reduction in the incidence 
of invasive pneumococcal disease after general 
vaccination with 7 -valent pneumococcal conjugate 
vaccine in German y. Vaccine 2009;27:4136 -41.03QYQQ
[Tomczy k, S., et al 
2014]Tomczy k S, Bennett NM, Stoecker C, Gierke R, Moore 
MR, Whitney  CG, et al. Use of 13 -valent pneumococcal 
conjugate vaccine and 23 -valent pneumococcal 
polysaccharide vaccine among adults aged is greater 
than or equal to 65 years: re commendations of the 
Advisory  Committee on Immunization Practices 
(ACI P). MMWR Morb Mortal Wkly  Rep. 2014 Sep 
19;63(37):822 -5.040XNF
[U.S. Food and Drug 
Administration 2009]U.S. Food and Drug Administration (CDER, CBER, 
CDRH). Guidance for industry  patient-reported outcome 
measures: use in medical product development to 
support labeling claims [Internet]. Washington: U.S. 
Department of Health and Human Services; 2009. 
Available from: 
https://www.fda.gov/downloads/drugs/guidances/ucm19
3282.pdf04MG9J
[Wagenvoort, G. H., et 
al 2016]Wagenvoort GH, Knol MJ, de Melker HE, Vlaminckx 
BJ, van der Ende A, Rozenbaum  MH, et al.  Risk and 
outcomes of invasive pneumococcal disease in adults 
with underlying conditions in the post -PCV7 era, The 
Netherlands. Vaccine. 2016 Jan 12;34(3):334 -40.04KTDB
[Waight, P. A., et al 
2015]Waight PA, Andrews NJ, L adhani SN, Sheppard CL , 
Slack MP, Miller E. Effect of the 13 -valent 
pneumococcal conjugate vaccine on invasive 
pneumococcal disease in England and Wales 4 y ears 
after its introduction: an observational cohort study . 
Lancet Infect Dis. 2015 May ;15(5):[ADDRESS_68591]: V114 103
PROTOCOL/AMENDMENT N O.: 016 -01 
V114 -016-01-FINAL PROTOCOL 01-JUN-2018
[Weiss, S., et al 2015] Weiss S, Falkenhorst G, van der Linden M, Imohl M, 
von Kries R. I mpact of 10 -  and 13- valent 
pneumococcal conjugate vaccines on incidenc e of 
invasive pneumococcal disease in children aged under 
16 years in German y, 2009 to 2012. Euro Surveill. 2015 
Mar 12;20(10):[ZIP_CODE].04KTFC
[Whitney , Cynthia G., 
et al 2003]Whitney  CG, Farley  MM, Hadler J, Harrison LH, 
Bennett NM, Lynfield R, et al. Decline in invasive 
pneumococcal disease after the introduction of protein -
polysaccharide conjugate vaccine. N Engl J Med 
2003;348(18):1737 -46.03QT0D 
  04Y2RW 
  05KFF2